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ABSTRACT 
Pathological conditions in the lower urinary tract are common and have a 
great impact on the quality of life for the patients suffering from such 
disorders. In this thesis cyclophosphamide (CYP)-induced cystitis, a well-
established rat model of inflammatory bladder diseases such as bladder pain 
syndrome/interstitial cystitis (BPS/IC), has been employed to study the role 
of purinergic transmission in the normal and inflamed state. The main focus 
was to characterize purinergic functional contractile and relaxatory 
parameters, studied in vitro, in vivo and in situ, for which the latter a novel 
method was developed and validated. The P2X1 purinoceptor was, in 
concordance with previous studies, found to be the major contractile subtype, 
whereas P2Y purinoceptor(s) with different sensitivities to the purinergic 
agonists ADP/ATP and UDP/UTP were shown to be relaxatory. Furthermore, 
the adenosine P1A2B purinoceptor was demonstrated to play a functional 
relaxatory role. 
Using the novel in situ experimental setup presented in this thesis it was 
concluded that stretch-evoked contralateral contractions, mediated by afferent 
nerve fibers, were increased during cystitis. This was in contrast to most 
other contractile studies, in which the response in the inflamed bladder was 
generally decreased. This enlargement to stretch stimulus was found to be 
due to both cholinergic and purinergic factors, of which the latter were more 
pronounced at lower stimulation intensities.  
 Since the purinoceptors are often mentioned in the context of inflammation, 
studies were also conducted to investigate the role of purinergic, as well as of 
cholinergic and nitrergic, blockade in the development of cystitis. It was 
concluded that blockade of the P1A1 purinoceptor or inhibition of nitric oxide 
synthase can alleviate the change in contractile function to CYP-induced 
bladder inflammation, which was confirmed by the study of several 
inflammatory findings common in cystitis. 
Taken together, the purinergic transmission is altered during cystitis, and the 
changes are likely predominantly on the afferent side of the micturition reflex 
arc. The novel in situ setup can be modified and used to study various 
afferent factors, without interfering with the contractility of the bladder. 
Future therapeutic drugs targeting purinoceptors on afferent neurons may 
provide a valuable addition to the currently used medicines. The fact that 
blockade of purinoceptors at the same time may have a beneficial impact on 
the inflammation itself may prove to be useful in the treatment of 
inflammatory conditions in the lower urinary tract. 
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POPULÄRVETENSKAPLIG 
SAMMANFATTNING PÅ SVENSKA 
Sjukdomar som påverkar urinblåsan är vanligt förekommande och orsakar 
lidande och sänkt livskvalitet för de personer som drabbas. I många fall, 
såsom vid sjukdomen interstitiell cystit, är urinblåsan inflammerad, vilket 
leder till rubbningar i urinblåsans förmåga att dra ihop sig och slappna av. 
Dessa funktioner styrs genom en komplex samverkan mellan olika 
transmittorsubstanser (kemiska signalmolekyler). 
Den viktigaste transmittorsubstansen för urinblåsans funktion är acetylkolin. 
Den utövar sin effekt genom att verka på mottagarprotein, muskarina 
receptorer, vilket generellt sett leder till att urinblåsemuskulaturen drar ihop 
sig. Dock har man sett att acetylkolin inte är ensam om att styra urinblåsan. 
Även signalmolekylen adenosintrifosfat (ATP) och dess nedbrytningsprodukt 
adenosin är av betydelse, speciellt vid sjukdom. Genom att verka på sina 
mottagarproteiner, purinoceptorerna, kan dessa ha effekt både på urinblåsans 
funktion och på själva sjukdomsförloppet. Även molekylen kväveoxid (NO) 
anses vara inblandad i inflammatoriska processer. 
I denna avhandling använder vi oss av djurförsök, där friska råttor samt råttor 
som blivit behandlade för att utveckla inflammation i urinblåsan jämförs. För 
att besvara problemställningarna har vi använt oss av experiment både på små 
bitar av urinblåsevävnad (in vitro) och på sövda råttor (in vivo). Dessutom har 
vi utvecklat en ny metod för att studera reflexer som är viktiga för 
urinblåsans funktion hos sövda råttor (in situ). Vi har även behandlat råttor 
med substanser som blockerar olika purinoceptorer och muskarina receptorer 
samt ett ämne som hämmar produktionen av NO. 
Vi fann att både ATP och adenosin, genom att binda till purinoceptorer av 
P2Y- och P1A2B-typ, kan göra så att muskelvävnaden i urinblåsan slappnar 
av. Dessutom visade vi, vilket bekräftar resultat från tidigare studier, att 
purinoceptorer av typen P2X1 orsakar sammandragning av urinblåsan. 
Vidare såg vi att den afferenta delen (signaler in till det centrala 
nervsystemet) av den reflex vi studerade in situ ökar under inflammation, och 
att purinoceptorer av typen P2 är involverade. Slutligen kunde vi visa att vi 
kan påverka sjukdomsförloppet och lindra de funktionsnedsättningar som 
uppkommer vid inflammation genom att hämma produktionen av NO eller 
genom att blockera P1A1-purinoceptorer. Detta bekräftade vi genom att 
undersöka ett antal inflammatoriska förändringar. 
 Våra fynd indikerar att framtida läkemedelsbehandling mot inflammatoriska 
tillstånd i urinblåsan skulle kunna riktas mot purinoceptorer. Dels då dessa är 
involverade i regleringen av urinblåsans funktion, framförallt då de verkar 
öka i betydelse i den afferenta delen av urinblåsans reflex. Dels då de, 
tillsammans med NO, kan påverka själva inflammationsförloppet. Trots att 
fler studier måste genomföras på detta område för att bekräfta dessa fynd, och 
för att undersöka om våra resultat stämmer även hos människor, är dessa 
upptäckter viktiga för vår förståelse av purinoceptorernas roll i urinblåsan vid 
sjukdom och hälsa. 
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1 INTRODUCTION 
The urinary bladder has two basic functions; to store urine and to voluntarily 
expel urine when suitable. This may seem to be rather simple tasks and, 
indeed, most of the time in most people it all works well. Nevertheless, 
dysfunctions and diseases of the urinary bladder are relatively common and 
have large impact on the quality of life of individual patients, as well as great 
economic implications on society. The exact mechanisms leading to many of 
the diseases are, despite much scientific effort, not fully understood and 
further studies are required to increase the knowledge of the complex systems 
involved. 
In this thesis different models for studying the impact of the purinergic 
system on the contractile and relaxatory function of the urinary bladder are 
addressed and a novel model for investigating the efferent and afferent parts 
of the micturition reflex is presented. Furthermore, the interplay between the 
purinergic system and the cholinergic and nitrergic systems in the functional 
regulation of the bladder and their respective importance in the development 
of inflammation are discussed and, thus, comparisons made between normal 
rats and ones with experimental cystitis. 
Models useful in the studies of disorders in the lower urinary tract have been 
employed and compared in Paper I. In Paper II and III in vitro findings 
regarding aspects of purinergic mechanisms in the function of the normal and 
inflamed urinary bladder are presented, whereas we in Paper IV utilize the 
novel approach presented in Paper I to investigate differences in the 
micturition reflex in normal rats and ones with experimental cystitis. In the 
two final papers, Paper V and VI, ways of preventing or alleviating the 
development of urinary bladder inflammation by purinergic, cholinergic and 
nitrergic pre-treatments are explored and different signs of inflammation and 
loss of function discussed. 
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1.1 The urinary bladder 
The urinary bladder is a hollow, smooth muscle organ serving the purpose of 
storing and, when suitable, releasing urine. Its regulation is governed by the 
autonomic nervous system. 
 
1.1.1 Anatomy and morphology of the urinary 
bladder 
The human urinary bladder is located in the pelvic cavity but can, when it is 
full, stretch also into the abdomen. The bladder base is formed like an 
inverted triangle and the ureters enter the bladder at the upper parts of its base 
and the urethra extends from its lowest point. The area between the two 
ureters and the urethra is known as the trigone (see Drake et al., 2005). The 
bladder wall consists of a mucosa layer, which includes the urothelium and 
the lamina propria, the submucosa and the detrusor smooth muscle (Fig. 1). 
The latter is generally considered to consist of three layers of smooth muscle; 
an outer longitudinal, a middle circular and an inner longitudinal layer. 
Outermost a serosal covering is found (see Martini et al., 2000). Even though 
the human urinary bladder can contain even larger volumes of urine, a first 
desire to void is usually felt at a volume of 150-200 ml and a sense of 
urgency at 400-450 ml (see Pocock et al., 2004). 
The rat urinary bladder has similar basic properties and weighs about 70 mg 
and the muscle layer is roughly 100 µm. Its inner diameters are 
approximately 14 x 9 mm and it can contain up to about 1.4 ml (Gabella et 
al., 1990).  
 
1.1.2 The urothelium 
The inner epithelial lining of the urinary bladder, often referred to as the 
urothelium, consists of cells organized in three layers, as summarized in a 
review by Lewis (2000). A basal layer containing small cells, an intermediate 
cell layer made up of moderately-sized cells and outermost large umbrella 
cells interconnected by tight junctions are found. The latter ones form a 
barrier preventing flow of molecules in the urine through the bladder wall. 
The umbrella cells are covered by hexagonal particles of crystalline proteins 
that, together with the tight junctions, form a flexible and very impermeable 
barrier. 
Patrik Aronsson 
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Figure 1. Structure of the (male) urinary bladder. Adapted from Wikipedia; 
http://commons.wikimedia.org/wiki/File:Illu_bladder.jpg 
 
Worth mentioning is also the layer of glycosaminoglycane (GAG) lining the 
inner surface of the bladder. This layer prevents leakage of small molecules, 
such as urea and calcium, from the bladder contents into, and through, the 
wall of the urinary bladder. Disruption of the GAG layer, for instance by 
instillation of protamine sulfate, leads to a loss of these substances from the 
urine (Parsons et al., 1990). In humans, disruption of the GAG layer has also 
been associated with urinary urgency and discomfort (Lilly et al., 1990). 
Previously the barrier function was considered to be the only property of the 
urothelium. More recent studies have, however, proven that the urothelium 
possesses also other qualities, including expressing receptors, releasing 
factors such as adenosine 5´-triphosphate (ATP) and nitric oxide (NO) 
(Birder et al., 1998; Ferguson et al., 1997). Afferent nerves have been found 
in the smooth muscle layers in the urinary bladder but also immediately 
adjacent to the urothelium with some of these nerve fibers extending into the 
urothelium (Birder et al., 2001). 
 
1.1.3 Innervation and the micturition reflex 
Autonomic sympathetic (e.g. the hypogastric nerve) and parasympathetic 
(e.g. the pelvic nerve), as well as somatic (the pudendal nerve) nerves are 
Ureteral opening
Trigone
Prostate gland
Ureter
Internal urethral orifice
Mucosa
Submucosa
Detrusor muscle
External urethral orifice
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mediating the efferent stimuli to the bladder. The parasympathetic nerve 
originates from sacral parts of the spinal cord and forms ganglia in the pelvic 
plexus and bladder wall. Upon activation it releases acetylcholine, the 
neurotransmitter responsible for the major contractile response of the urinary 
bladder by acting on muscarinic M3 receptors in the detrusor (Longhurst et 
al., 1995; Wang et al., 1995). Furthermore, these nerves may co-release non-
adrenergic, non-cholinergic (NANC)-transmitters such as ATP (mainly 
contractile) and NO (mainly relaxatory). The somatic nerve fibers also 
release acetylcholine acting on nicotinic cholinergic receptors mediating 
voluntary contraction of the striated muscle of the outer sphincter, see 
Yoshimura et al. (2008). 
The sympathetic nerve fibers emerge from the thoracolumbar segments of the 
spinal cord and form the postganglionic hypogastric nerve. These nerves 
release noradrenaline which, in turn, activates β-adrenoceptors mediating 
relaxation of the detrusor smooth muscle, and α-adrenoceptors which mediate 
contraction of the “out-flow regions” of the urinary bladder, i.e. the bladder 
neck and urethra (Perlberg et al., 1982; Yamaguchi, 2013). Thus, activation 
of sympathetic and somatic nerves puts the urinary bladder in the “filling 
phase”, whereas stimulation of the parasympathetic nerves causes the 
opposite response, i.e. micturition/voiding. Furthermore, the autonomic 
nerves carry afferent signals of filling from the urinary bladder to the spinal 
cord and the pudendal and hypogastric nerve transmit similar signals from the 
urethra and bladder neck (Fowler et al., 2008), a sensory feedback proven to 
be of importance for efficient voiding in the rat (Peng et al., 2008). Despite 
many studies showing that afferent input from the bladder can arise in 
different parts of the bladder, i.e. detrusor, urothelium and lamina propria, the 
micturition reflex can be considered to originate mainly from activation of 
stretch receptors in the bladder wall, as a response to bladder filling (Kanai et 
al., 2010). 
Two types of neurons are of importance in the afferent signaling of the 
urinary bladder. Most important regarding bladder filling in the normal 
condition are the glutamatergic Aδ-fibers (de Groat et al., 1990). These 
myelinated fibers mediate signals of bladder filling by responding to 
distention and contraction of the urinary bladder. The other neuron type is 
unmyelinated C-fibers, which transmit signals in response to cooling or 
chemical irritation, and in which substance P and calcitonin gene-related 
peptide are transmitters. Of interest in the perspective of the methods used in 
the current thesis, as discussed below, may be the fact that acrolein acting on 
the sensory nerve fiber TRPA1 receptor (belonging to the transient receptor 
potential superfamily) likely activates this latter type of fibers (Bautista et al., 
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2006; Streng et al., 2008). The C-fibers do, however, not seem to be a 
necessity for micturition (de Groat et al., 1981). A receptor subtype 
expressed on afferent bladder nerves regarded to be of great importance in 
the micturition reflex is the P2X3 purinoceptor (Cockayne et al., 2000). 
However, heteromeric purinoceptors containing the P2X2 subunit have also 
been implicated (Cockayne et al., 2005). 
The existence of a micturition controlling center in the brainstem was 
discovered almost a century ago when it was shown that, in cat, lesions in the 
dorsolateral pontine tegmentum inhibited the reflex involved in micturition 
(Barrington, 1925; Barrington, 1914). Electrical stimulation of this 
supraspinal center, called Barrington's Nucleus or the pontine micturition 
center (PMC), causes bladder contraction that seems to be gradually 
increased over time, i.e. the contractions were smaller just after a previous 
stimulation, compared to contractions after a longer period of resting (Noto et 
al., 1989). Bladder relaxation is usually not accredited the PMC, but is rather 
believed to be exerted by a center in the ventrolateral part of the pontine 
tegmentum (Blok et al., 1999) or the rostral part of the pontine reticular 
formation. For an excellent review on the subject of the PMC and 
micturition, see Sasaki (2005). 
In the discussion of even higher level centers being of importance for the 
micturition reflex, the periaqueductal gray (PAG) in the midbrain is usually 
mentioned. It has been demonstrated that electrical stimulation of the PAG 
induces bladder contraction in the rat (Kruse et al., 1990). Recent studies 
have, however, shown that, at least in the cat, PAG is not essential for 
evoking micturition, but that the Barrington's nucleus/PMC on the other hand 
is (Takasaki et al., 2010). Most likely, the PAG is rather an important “relay 
station” in voluntary micturition, funneling signals from higher brain centers 
involved (Nour et al., 2000). Interestingly, P2 purinoceptors have been 
shown to be of importance in both Barrington's nucleus and PAG in terms of 
generating activity in parasympathetic nerves supplying efferent input to the 
urinary bladder (Rocha et al., 2001). 
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1.2 Diseases of the urinary bladder 
Inflammation of the urinary bladder commonly referred to as “cystitis”, and 
other more general disturbances such as overactive bladder are common 
disorders, which profoundly affects individual patients and are of great 
economical concern for society. Although several different diseases exist, the 
symptoms are often to a large extent overlapping, showing similar features 
such as functional disturbances, urinary urgency, frequency and pain or 
discomfort. Despite much effort the exact mechanisms underlying these 
diseases are still largely unknown. 
The focus of this thesis is directed towards non-infectious inflammatory 
bladder diseases, and even though bladder pain syndrome/interstitial cystitis 
may seem to show the most resemblance with the animal models used, 
overactive bladder is also often studied in this way and, thus, discussed in the 
thesis. 
 
1.2.1 Overactive bladder 
Overactive bladder (OAB), sometimes called “detrusor overactivity”, is 
defined by the International Urogynecological Association (IUGA) and the 
International Continence Society (ICS) as: “urinary urgency, usually 
accompanied by frequency and nocturia, with or without urgency urinary 
incontinence, in the absence of urinary tract infection or other obvious 
pathology” (Haylen et al., 2010). Usually, OAB is subdivided into two 
groups, OABDRY and OABWET, the latter describing patients with concomitant 
incontinence. 
The prevalence of OAB has been estimated in numerous studies, but the 
numbers usually comes down to approximately 15% of the total population 
(Milsom et al., 2001). OAB is about as common in women as in men, with 
some studies suggesting an increased prevalence in women, and the risk of 
developing OAB increases with age (Milsom et al., 2001; Temml et al., 
2005; Wennberg et al., 2009). The annual national cost for OAB treatment 
has in the United States been estimated to $65.9 billion (Ganz et al., 2010). 
Assuming that most parameters are comparable between Sweden and USA, 
this would correspond to roughly 13 billion SEK in Sweden per year. 
The mechanisms causing OAB are not fully understood, but both neurologic 
and myogenic factors are regarded to be of importance in the development of 
the disease, as summarized by Brading (1997), de Groat (1997) and Miller et 
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al. (2006). The pharmacological treatment of OAB consists mainly of anti-
muscarinic drugs, whose main mechanism of action has been attributed to the 
blockade of contractile muscarinic receptors, but which may also be due to 
the inhibition of muscarinic receptors responsible for facilitating the release 
of ATP affecting afferent signaling (Nicholas et al., 1996). Alternative 
treatments include injections of botulinum toxin which blocks the release of 
acetylcholine, and also the co-release of ATP, from efferent nerve fibers, 
thereby relaxing the bladder (Lawrence et al., 2010). 
 
1.2.2 Interstitial cystitis and Bladder pain 
syndrome 
Among the earliest cases of interstitial cystitis (IC) found in the scientific 
literature is that of Alexander Skene, who described an inflammatory 
condition disrupting the mucous barrier, affecting also the muscular layers of 
the urinary bladder (Skene, 1887). Since then, this disease has been defined 
based on its resistance to conventional therapies (Hunner, 1915) and 
characterized based on its symptoms, which include a constant need to 
urinate (frequency) and pain (Bourque, 1951). 
Today the term bladder pain syndrome (BPS) “largely replaces the older 
Interstitial Cystitis term, but the two are essentially interchangeable as there 
is no accepted definition that clearly delineates the interstitial cystitis 
syndrome from bladder pain syndrome” (Abrams et al., 2009). The current 
definition of BPS, used by the International Continence Society, is “the 
complaint of suprapubic pain related to bladder filling, accompanied by other 
symptoms such as increased daytime and night-time frequency, in the 
absence of proven urinary infection or other obvious pathology” (Abrams et 
al., 2002). More recently, the American Urological Association (AUA) used 
the guidelines developed by the Society for Urodynamics and Female 
Urology, stating “BPS/IC to be “an unpleasant sensation (pain, pressure, 
discomfort) perceived to be related to the urinary bladder, associated with 
lower urinary tract symptom(s) of more than 6 weeks duration, in the absence 
of infection or other identifiable causes” (Hanno et al., 2011). 
 
The prevalence of BPS/IC in the general population has been shown to be 
hard to estimate, in particular since different forms of questionnaires are 
being used. Two of the most commonly used forms have been compared, 
suggesting a prevalence of BPS/IC in women between 0.57-12.6% of the 
general population, most likely somewhere in between these two extremes 
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(Rosenberg et al., 2005). Other studies have found the prevalence of 
clinically confirmed IC to be 300 per 100 000 in the female population 
(Leppilahti et al., 2005), with women found to be about five times more 
likely than men to suffer from BPS/IC (Clemens et al., 2005). These latter 
numbers are in line with the current opinion of the International Continence 
Society (Abrams et al., 2009). 
Even though much effort has been spent to understand the etiology of 
BPS/IC, the mechanisms leading to this condition are not yet fully 
understood, but the disease is regarded to be of multifactorial origin. 
Commonly mentioned proposed underlying mechanisms are inflammation, 
mast cell activation, changes in neuronal function, cross-talk between pelvic 
organs (regarding e.g. inflammation and pain) and autoimmune mechanisms 
(Abrams et al., 2009; Vij et al., 2012). Also, one feature in IC that may 
contribute to both the progression and the symptoms of the disease is the fact 
that the urothelium, including the GAG layer, often is damaged in patients 
suffering from this illness. The loss of barrier function is even greater in 
patients with ulcerative IC than in patients without ulcers, but also the latter 
group displays a pronounced increase in permeability to small molecules 
compared to healthy subjects (Parsons et al., 1991). 
As a consequence, no optimal treatment has been produced until this day, 
even though a number of pharmacological and non-pharmacological 
treatments have been evaluated. Among the non-pharmacological suggested 
are changes in diet, behavioral modification and physical therapy (Gish, 
2011; Vij et al., 2012). Often discussed pharmacological treatments include 
oral doses of the immunosuppressant cyclosporine A, the tricyclic 
antidepressant amitriptyline or pentosan polysulphate sodium. Also, 
intradetrusorial injections of botulinum toxin serotype A and intravesical 
treatment with dimethyl sulfoxide (DMSO) are established methods. 
Although a recent meta-analysis concluded the use of cyclosporine A to be of 
best proven use, the evidence are not clear-cut and much remains to be done 
in the pharmacological treatment of BPS/IC (Giannantoni et al., 2012). 
Regarding purinergic alterations in BPS/IC, it has been demonstrated that 
urinary ATP levels are elevated and that the release of ATP to stretch of 
urothelial cells is increased in patients with this disease (Sun et al., 2001). 
Studies in the cat partly support this, showing that urothelial cells from 
animals with feline interstitial cystitis exhibit increased stretch-induced ATP 
release, although no difference was observed at a basal level, suggesting a 
mechanical hypersensitivity (Birder et al., 2003). Other investigations have 
shown a reduced expression of, mainly, P2X1 purinoceptors in the bladder 
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smooth muscle and urothelium in this feline IC model (Birder et al., 2004). 
Furthermore, in vitro examinations of bladder strip preparations from patients 
with and without BPS/IC have suggested that the purinergic signaling may be 
minute, or even absent, in healthy humans (Kinder et al., 1985), but of 
markedly increased importance in patients with this disorder (Palea et al., 
1993). 
 
1.2.3 Cyclophosphamide- induced cystitis 
Cyclophosphamide (CYP) is an anti-neoplastic drug used in the treatment of 
certain forms of cancer, well known for its common side-effect of causing 
cystitis in patients. About 10% of the patients treated with high doses (>20 
mg/kg) or for extended periods of time develop aseptic cystitis 
(Läkemedelsindustriföreningens Service AB, 2012). This side-effect has, 
however, led to the usage of CYP as an agent for causing experimental 
cystitis in animals, a method that is now widely established and used as a 
model for studying both BPS/IC and OAB. Two principal ways to induce 
cystitis by CYP exist; either by a single injection or by repeated injections of, 
usually, lower doses (as discussed in Boudes et al., 2011). 
The exact mechanism behind the induction of cystitis by CYP is not fully 
understood, but is regarded to be due to the contact of a metabolite of CYP 
with the urothelium. This has been demonstrated in studies in the dog, where 
cystitis has been induced by CYP-injection and the urine collected. The 
collected urine evoked, when instilled into another dog’s urinary bladder, 
cystitis, unlike normal urine mixed with CYP which did so only to a minor 
extent (Philips et al., 1961). The metabolite responsible has later been 
confirmed to be acrolein (Cox, 1979; Levy et al., 1977).  
Also, afferent nerves (capsaicin-sensitive primary afferent neurons) are 
believed to be of importance in the development of CYP-induced cystitis, 
indicating a possible mechanism for disorders in the lower urinary tract 
(Ahluwalia et al., 1994). Interestingly, in CYP-induced cystitis, a substantial 
neurogenic inflammatory component has been suggested, as discussed by 
Geppetti et al. (2008). Furthermore, NO seems to have a significant impact in 
CYP-induced cystitis and the instillation of NO-donor into the bladder 
reduces the hyperactivity of the detrusor seen in this animal disease model, 
either by direct smooth muscle relaxation or by affecting afferent nerves 
(Ozawa et al., 1999). 
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Alternative animal models to CYP-induced cystitis include feline 
spontaneous cystitis, neurogenic cystitis (due to stimulation of afferent 
nerves), and the use of other irritants besides CYP, such as 
lipopolysaccharide (LPS), turpentine or acid, as has been reviewed by 
Bjorling et al.(2011). 
 
1.2.4 Markers for cystitis 
Many markers have been suggested to be of potential clinical relevance in the 
diagnosis of diseases affecting the lower urinary tract. One of the more well-
studied ones, see Mamedova et al. (2004) is antiproliferative factor (APF), 
which has been found to be produced by urothelial cells derived from BPS/IC 
patients, but not from healthy controls (Boyer et al., 1998). This factor is 
suggested to inhibit the production of heparin-binding epidermal growth 
factor–like growth factor (HBEGF), which is significantly reduced in patients 
suffering from BPS/IC (Mamedova et al., 2004). Interestingly, APF is 
increased only in the urine contained in the bladder, and not in urine samples 
collected directly from the renal pelvis (El-Tayeb et al., 2006). Besides 
increased levels of APF and decreased levels of HBEGF, the expression of 
epidermal growth factor (EGF) is generally regarded to be elevated in urine 
from patients with BPS/IC (Mamedova et al., 2004), and many other 
inflammation markers, such as tumor necrosis factor-alpha, insulin-like 
growth factor 1 (IGF-1), insulin-like growth factor-binding protein 3 
(IGFBP3) and several interleukins have been suggested to be linked to 
IC/BPS (Crack et al., 1994; Keay et al., 1997). 
More recently, macrophage migration inhibitory factor (MIF) has been 
identified as being of great interest when studying inflammation in the 
urinary bladder. MIF is a cytokine with proinflammatory properties 
expressed in the urinary bladder tissue, as well as in nerves supplying the 
bladder (Vera et al., 2003). MIF has been shown to be increased during 
cystitis induced by LPS (Meyer-Siegler et al., 2004a) or CYP in the rat (Vera 
et al., 2008). Furthermore, inhibition of MIF-activity has been demonstrated 
to decrease the effects of CYP-induced cystitis in mice, strengthening the 
claim that this cytokine may be of importance in modulating and maintaining 
the inflammation process (Vera et al., 2010). 
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1.3 Purinergic signaling 
Although the main contractile transmitter of the urinary bladder is 
acetylcholine, it has long been known that a part of the contractile response 
of the urinary bladder is in many species insensitive to the muscarinic 
antagonist atropine (Langley et al., 1895). This phenomenon, usually termed 
“atropine resistance”, inspired other scientists into looking for still unknown 
non-adrenergic, non-cholinergic (NANC) transmitter systems. The results of 
these investigations included findings of adenine compounds (i.e. purines), 
especially adenosine, being present in the animal body and exerting 
significant cardiovascular effects such as bradycardia and hypotension, the 
latter partly due to arterial dilatation (Drury et al., 1929). In the same year 
triphosphates, including ATP, were extracted and identified in muscle and 
liver (Fiske et al., 1929; Lohmann, 1929). Efforts were later made to study 
the physiological effects of ATP on muscle preparations, showing direct 
contractile effects and implying a potentiating role of ATP to acetylcholine 
(Buchthal et al., 1944a; Buchthal et al., 1944b). The effects of ATP were 
however interpreted in different ways and it was, for instance, stated that 
"[...] it is not the ATP itself which produces the contraction, but that it 
releases from the muscle preparation acetylcholine or an acetylcholine-like 
substance which then in its turn elicits the contraction" (Beznak, 1951). 
Eventually, it was also demonstrated that ATP could be released from 
sensory nerves when stimulated (Holton, 1959). 
 
1.3.1 A purinergic transmission? 
What is usually described as a breakthrough in understanding the importance 
of purinergic signaling took place in the early 1960s when Geoffrey 
Burnstock and his colleagues performed a series of experiments in which 
they blocked both cholinergic and adrenergic receptors, as well as using 
bretylium to inhibit release of transmitters from sympathetic nerves 
(Burnstock et al., 1963; Burnstock et al., 1966). Contrary to what was 
expected, they found relaxation and rapid hyperpolarization to single stimuli. 
These new observations, combined with the earlier findings, led to the 
conclusions that only a part of the relaxation seen could be attributed to the 
classical autonomic nervous system and that the inhibitory responses still 
present after blockade were “mediated by intrinsic nerves which are distinct 
from the sympathetic and parasympathetic systems” (Burnstock et al., 1964). 
By combining the earlier findings regarding physiological effects of ATP 
with new data, the term “purinergic” was finally coined (Burnstock, 1971) 
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and the concept of purinergic transmission was established (Burnstock, 
1972). 
 
1.3.2 ATP as a transmitter 
In order to be recognized as a transmitter a substance has to fulfill certain 
requirements. The definitions vary, but they are usually adaptions of the one 
presented by Eccles (1964), even though they are sometimes expanded in 
more recent literature (Guarna et al., 2005; Purves, 2012). Generally, it is 
said that in order to be classified as a neurotransmitter the substance and the 
enzymes necessary for its synthesis must be present in the neuron and the 
substance released from the terminal axon upon nerve activation (i.e.  
Ca2+-dependent depolarization). Furthermore, a mechanism able to rapidly 
inactivate the response should be present in the synapse and it must be 
possible to mimic the physiological effects of the transmitter by 
administering it exogenously, allowing it to act on the same postsynaptic 
receptors on the effector tissue as the neurotransmitter usually does. All these 
requirements have now been shown to be fulfilled by ATP and will be dealt 
with in more depth below. 
 
1.3.2.1 Purinergic co- transmission 
One often used expression is that of “Dale’s principle”, which has been 
interpreted in several different ways. Eccles et al. (1954), who first coined 
this expression, used it in the sense implying the same chemical transmitter 
being released from all the synapses of a single neuron (i.e. stating that 
individual neurons are either adrenergic or cholinergic ones and that one 
nerve uses only one chemical transmitter). The original work he was referring 
to did, however, not explicitly claim this. It rather stated the chemical 
function of each neuron to be specific for this neuron as well as being 
“unchangeable” (Dale, 1935).  
Even though there were clues in the literature, the formal proposal of the term 
“co-transmission”, the concept of release of several chemical transmitters 
from one nerve simultaneously, was not published until 1976 (Burnstock, 
1976). In this paper the “Dale’s principle” (in the sense of one nerve – one 
transmitter) was openly challenged. It is, however, worth noticing that other 
researchers of that time had similar ideas. Silinsky, for instance, suggested 
ATP derived from cholinergic vesicles to be released from the motor nerve 
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ending (Silinsky, 1975), and also Eccles slightly but importantly rephrased 
his previous interpretation of Dale’s principle, suggesting that “[…] at all the 
axonal branches of a neurone, there was liberation of the same transmitter 
substance or substances” (Eccles, 1976), thus opening up for the possibility 
of multiple chemical transmitters being released from the same nerve ending. 
The concept of purinergic co-transmission has been suggested, and later 
proven, also in sympathetic nerves. Stimulation of sympathetic nerves in the 
guinea-pig vas deferens elicited chemical transmission that was shown to 
consist of more than just noradrenaline (Ambache et al., 1971). Further 
studies made likely that ATP serves as a neuromodulator and/or co-
transmitter to noradrenaline (Su, 1975; Westfall et al., 1978), and by using 
the, at the time, novel purinoceptor desensitizer α,βMe-ATP this was proven 
to be accurate both in the guinea-pig (Sneddon et al., 1984) as well as, later, 
in man (Banks et al., 2006). 
 
1.3.2.2 Formation and storage of neuronal ATP 
Although mammalian cells are capable of de novo synthesis of 
adenine/adenosine, it is usually formed in various metabolic reactions, and 
can be absorbed by nerve terminals and further converted to ATP by 
oxidative phosphorylation (Sperlágh et al., 1996). It has been shown that 
exogenous tritium-labeled adenosine can be converted to ATP and 
subsequently released from neurons in the taenia coli (Su et al., 1971). 
Evidence of ATP being stored in vesicles was first presented in a study of 
cholinergic vesicles from Torpedo marmorata, the marbled electric ray 
(Dowdall et al., 1974). It was found that the vesicles located in the nerve 
terminals of the electric organ of this ray contained not only acetylcholine, 
but also considerable amounts of ATP. When enzymes were added in order to 
remove free substances, the ATP within the vesicles was found to remain 
intact. Furthermore, it was demonstrated that the ATP inside the vesicles was 
not just “trapped” there during their formation and that the ratio of vesicular 
acetylcholine to ATP was rather robust, about 5:1, in a series of experiments.  
The vesicular uptake of ATP remained poorly characterized until a study of 
its kinetics was presented at the end of the millennium. Using florescent 
adenine nucleotide analogues, including labeled ATP, the presence of 
nucleotide transporters was confirmed in the rat brain (Gualix et al., 1999). 
 
Purinergic Effects in the Rat Urinary Bladder 
14 
1.3.2.3 Release of ATP 
Studies on rat brain tissue have shown that stimulation with a secretagogue, 
for instance veratridine, releases the contents of synaptic vesicles, including 
ATP, in a Ca2+-dependent manner (Pintor et al., 1992). The same is true for 
chromaffin cells, modified postsynaptic sympathetic nerve cells able to 
release adrenaline and noradrenaline into the bloodstream instead of directly 
affecting an effector tissue (Pintor et al., 1993). Recently, the neuronal 
release of ATP has been shown to be quantal in nature, suggesting exocytotic 
vesicular release (Pankratov et al., 2007). 
Non-neuronal release of ATP can be evoked in many different types of tissue 
by, for instance, stretch and shear stress. Urothelial cells release ATP upon 
stretch, which has been suggested to constitute a sensory mechanism for 
bladder filling (Ferguson et al., 1997). It has also been demonstrated that the 
release of ATP from the urothelium occurs at both the serosal and mucosal 
sides (Wang et al., 2005). Vascular endothelial cells release ATP when 
subjected to shear stress (Bodin et al., 1991), by a mechanism involving 
exocytosis of ATP-containing vesicles, similar to those in neuronal synapses 
(Bodin et al., 2001).  
 
1.3.2.4 Breakdown and removal of neuronal ATP and 
adenosine 
Once released into the synaptic cleft, ATP and its phosphorous metabolites 
are rapidly inactivated and removed. Several enzymes, both soluble and 
membrane bound, involved in these processes have been described. The main 
enzyme families responsible for these actions are currently being identified as 
the ecto-nucleoside triphosphate diphosphohydrolases (E-NTPDases), ecto-
nucleotide pyrophosphatase/phosphodiesterases (E-NPPs), ecto-5'-
nucleotidases/CD73, and alkaline phosphatases (Yegutkin, 2008). 
Enzymes of the E-NTDPase, previously also known as ecto-ATPase, ATP-
diphosphohydrolase, nucleoside diphosphatase etc., family are found 
intracellularly as well as bound to the cell membrane and can also be secreted 
extracellularly. In the context of ATP, the E-NTDPases metabolize 
nucleotide triphosphates (e.g. ATP to ADP) and nucleotide diphosphates (e.g. 
ADP to AMP), but do not further metabolize monophosphates, such as AMP 
(Zimmermann, 1996). The E-NPP family can hydrolyze triphosphates, but is 
mainly responsible for the breakdown of diphosphates in vertebrates 
(Vollmayer et al., 2003). The E-NPPs have, as do the E-NTDPases, a rather 
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broad substrate specificity, sometimes making the discrimination between the 
two families somewhat difficult. 
The ecto-5'-nucleotidases/CD73 are generally considered to be membrane 
bound, although some studies report possible soluble forms (Yegutkin et al., 
2000). This enzyme family is capable of forming adenosine by 
phosphohydrolysis of AMP (Colgan et al., 2006).  
Finally, the alkaline phosphatases are a family of abundant enzymes with 
broad range specificity, including dephosphorylation of ATP, ADP as well as 
AMP. The overall role of this family in purinergic signaling is, however, not 
that well investigated (Zimmermann, 2000). Thus, the alkaline phosphatases 
are, together with the ecto-5'-nucleotidases, responsible for the conversion of 
nucleoside phosphates to adenosine. It has been demonstrated that about 50% 
of the extracellular adenosine available is the result of the break-down of 
ATP (Smith, 1991) which is currently regarded to be the most important 
route of generating extracellular adenosine (Zhang et al., 2012). In vitro, 
degradation studies of ATP in a guinea-pig detrusor strip organ bath setup 
showed that ATP was rapidly broken down within minutes to form mainly, 
but not exclusively, adenosine (Cusack et al., 1984). 
The break-down of adenosine is, in turn, facilitated by one of several 
mechanisms, of which the one most commonly discussed in the literature is 
adenosine deaminase (ADA). Adenosine deaminase is responsible for the 
catabolism of adenosine to inosine and the enzyme can be found both intra- 
and extracellularly (Spychala, 2000). Some studies also claim possible ADA 
expression on the surface of dendritic cells, constituting a regulatory 
mechanism in, for instance, the regulation of inflammation (Desrosiers et al., 
2007). 
 
1.3.3 Purinergic receptors  
The characterization of these receptor families, also known by the collective 
name “purinoceptors”, have been an ongoing work since the 1970’s when a 
seminal review was published, discussing a possible separation into P1 and 
P2 purinoceptors, based on four criteria (Burnstock, 1978). The first two 
were the relative potencies of the agonists, i.e. ATP, ADP, AMP and 
adenosine and the effects of selective antagonists, capable of inhibiting the 
response to adenosine, but not that evoked by ATP. The third and fourth 
criteria, the modulation of adenylate cyclase resulting in altered levels of 
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cyclic adenosine monophosphate (cAMP) by adenosine (but not ATP) and 
the generation of prostaglandin synthesis by ATP (but not by adenosine), 
were also investigated, as summarized by Abbracchio (1994). This view was 
maintained, and the P2 family was eventually further subdivided into the P2X 
and P2Y purinoceptors (Burnstock et al., 1985). 
To date, these receptors for purine and pyrimidine nucleotides are still 
divided into the adenosine receptors (also known as the P1 purinoceptors), 
the P2X purinoceptors and the P2Y purinoceptors. A somewhat aged, but still 
very comprehensive review article that provides a major part of the collective 
knowledge in the field of purinergic receptors was published at the end of the 
last century (Ralevic et al., 1998). 
 
1.3.3.1 Adenosine P1 purinoceptors 
The adenosine receptors, or P1 purinoceptors, are G protein-coupled 
receptors of which four subtypes have currently been identified and whose 
naturally occurring ligand is adenosine (Fredholm et al., 2012; Fredholm et 
al., 2011). For long the P1 purinoceptors were thought to exist only in a 
monomeric state. This has however been disproved and, for instance, 
homomeric A2A-A2A receptors have been identified and suggested to be of 
functional importance on the cell surface (Canals et al., 2004). Furthermore, 
oligomeric association of P1A1 adenosine receptor subunits with non-
adenosine receptor proteins, such as P2Y1 purinoceptor subunits, has been 
described (Yoshioka et al., 2001). 
 
1.3.3.2 P2X purinoceptors 
As of today, seven subtypes of the P2X purinoceptor family, termed P2X1; 
P2X2; P2X3; P2X4; P2X5; P2X6 and P2X7 have been identified, by cloning 
and pharmacological classification (Evans et al., 2012). Notably these 
receptors are expressed either as homomeric (e.g. P2X1) or heteromeric 
trimers (e.g. P2X2/3), and seem to require binding of one, two or three 
molecules of their endogenous ligand ATP to be activated. An extensive 
recent review on the P2X subfamily of purinoceptors is available (Coddou et 
al., 2011). 
Being ionotropic ligand gated ion channels, the P2X purinoceptors today 
follow the same nomenclature as the rest of the members of this superfamily, 
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thus the use of subscripts in the subunit names has been abandoned for this 
family in accordance with the guidelines recently presented by The 
International Union of Basic and Clinical Pharmacology (IUPHAR) 
(Collingridge et al., 2009).  
 
1.3.3.3 P2Y purinoceptors 
The P2Y purinoceptor superfamily currently contains eight mammal 
subtypes, namely the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and 
P2Y14 purinoceptors, all of which are G protein-coupled (metabotropic) 
receptors (Burnstock et al., 2012). The first P2Y purinoceptor was cloned in 
1993 (Webb et al., 1993), but since then there has long been controversy 
regarding the classification and identification of the P2Y purinoceptors, 
leading to the use of many now unofficial names such as “platelet ADP 
receptor” (P2Y1), “P2U” (P2Y2), “P2YADP” and “P2TAC”, (P2Y12) etc. 
(Burnstock et al., 2012; Ralevic et al., 1998). 
Unlike the P2X purinoceptors, whose primary endogenous agonist is ATP, 
both ATP and ADP are regarded as naturally occurring agonists for the P2Y 
superfamily, even though the subtypes differ greatly in sensitivity. For 
instance, the human P2Y1 purinoceptor has been shown to be stimulated by 
ADP, while ATP in some cases can act as an antagonist at this receptor (Leon 
et al., 1997). Other P2Y purinoceptors, such as the P2Y2, have ATP (or UTP) 
as endogenous agonist rather than the dinucleotides (i.e. ADP and UDP) 
(Nicholas et al., 1996). 
The current nomenclature of the mammal P2Y purinoceptor subtypes are, 
according to IUPHAR, to state the subtype number in subscript, i.e. P2Ynumber 
(Burnstock et al., 2012). 
 
1.3.3.4 Expression in the urinary bladder 
Immunoreactivity for all seven subtypes of the P2X purinoceptor has been 
detected in the rat urinary bladder (Lee et al., 2000). Also, mRNA for all 
subtypes of P2X purinoceptors has been identified in the rat bladder (Creed et 
al., 2010). In mice the P2X3 purinoceptor has been shown to be expressed at 
sensory neurons in the bladder and this subtype is regarded to be of 
importance in the voiding reflex (Cockayne et al., 2000). 
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In the human bladder, RNA for five of the P2X purinoceptor subtypes has 
been detected, showing the P2X1 subtype to be the predominant one whereas 
no transcripts were found for the P2X3 or P2X6 subtypes (O'Reilly et al., 
2001). Furthermore, other studies have shown expression of all seven P2X 
subtypes in immunohistochemical studies in man (Moore et al., 2001). P2X3 
has, together with P2X2, been shown to be expressed in the human bladder 
urothelium in increasing magnitude in patients with IC (Tempest et al., 
2004). 
Regarding the P2Y purinoceptors, the P2Y1, P2Y2, and P2Y4 subtypes have 
been identified in the feline urothelium (Birder et al., 2004), and, in addition, 
the P2Y6 subtype has been identified in the guinea-pig (Sui et al., 2006). 
Transcripts for P2Y1, P2Y2, and P2Y11 purinoceptors have been found in 
human urothelial cell lines (Save et al., 2010). 
Additionally, western blot analysis has confirmed the expression of all four 
subtypes of adenosine receptors in the human urothelium (Yu et al., 2006). 
Also, RT-PCR has successfully been used to identify mRNA for all subtypes 
in the rat urinary bladder (Dixon et al., 1996). 
 
1.3.3.5 Adenosine P1 purinoceptors in inflammation 
It is no overstatement that the role of P1 purinoceptors in inflammation is 
complex, as has recently been thoroughly reviewed by Blackburn et al. 
(2009). Adenosine receptors are present on all types of immunological cells 
and all four subtypes have been shown to possess both anti- and pro-
inflammatory properties in different cell types and under various conditions. 
Notably, inflammatory cells, such as mast cells, can also release adenosine 
(and ATP) when stimulated (Marquardt et al., 1984). 
 
1.3.4 Relevance of purinergic functional signaling 
in the urinary bladder 
Administration of ATP to in vitro detrusor strip preparations causes a rapid 
contraction followed by a sustained relaxation. While the P2X purinoceptors 
are regarded to be mainly contractile, the P2Y purinoceptors are believed to 
be predominantly relaxatory (Bolego et al., 1995; Inoue et al., 1990). It has 
been suggested that ATP may be a key player in the initiation of voiding by 
giving rise to a fast contraction of the urinary bladder which in turn makes 
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possible the slower, more powerful and longer-lasting cholinergic contraction 
(Chancellor et al., 1992; Streng et al., 2004). Regarding actual voiding, it has 
in the rabbit been demonstrated that the response to ATP causes the urinary 
bladder to expel only about 15% of its contents, which is close to that of 
electric field stimulation in the presence of atropine (Levin et al., 1986). It 
has been suggested that this swift low-volume purinergic voiding may be of 
great importance in territorial marking animals.  
In man, as mentioned previously, the direct functional effects of the 
purinoceptors seem to be small in healthy humans, but the impact of 
purinergic signaling is elevated in certain diseases and medical conditions 
(Bayliss et al., 1999; Kinder et al., 1985; Palea et al., 1993; Sjogren et al., 
1982). Furthermore, it has been demonstrated that the atropine-resistant 
component of electrical field stimulation-induced contractions increases and 
that the purinergic neurotransmission is elevated in the aged human bladder 
(>70 years of age), whereas cholinergic neurotransmission shows a negative 
correlation to age (Yoshida et al., 2001). Possibly, the atropine-resistant 
parasympathetic response may have been underestimated because of 
underestimation of the complexity of transmitter interactions, as is indicated 
in this thesis. 
 
1.3.5 Examples of practical current 
pharmacological modulation of the 
purinergic system 
The worlds perhaps most common psychoactive drug, namely caffeine, acts 
as an antagonist on adenosine P1 purinoceptors, thereby promoting alertness. 
The purinoceptor subtypes being blocked are P1A1 and P1A2A, and the 
current opinion is that the latter is mediating the arousal effect (Huang et al., 
2005). Another drug inhibiting adenosine receptors of the P1A subtypes is 
theophylline (Daly et al., 1987), which has in the past been used in the 
treatment of bronchial asthma, although its mechanism of action is not fully 
unraveled.  
Regarding the P2 purinoceptors, clopidogrel is a well-known anticoagulatory 
drug (antiaggregant). Its mechanism of action is to block P2Y12 purinoceptors 
on platelets, eventually inhibiting platelet aggregation and thus reducing the 
risk of blood clots (Geiger et al., 1999). 
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1.4 Purinergic interactions with other 
transmitter and modulator systems 
Apart from being a functional system on its own, the purinergic system also 
affects, and is affected by, other chemical transmitters and modulators. Many 
such substances have been implicated and two of them, namely acetylcholine 
and NO, are in the scope of this thesis important to discuss specifically. 
 
1.4.1 Cholinergic systems 
The discovery of acetylcholine as a major chemical transmitter in the body is 
usually accredited to Henry Dale and Otto Loewi. The former identified this 
substance in ergot extracts and investigated its pharmacological effects. 
Loewi later demonstrated that stimulation of the vagal nerve of the frog 
caused a reduction of the heart rate. When the stimulated heart was 
cannulated and rinsed with Ringers solution the resulting perfusate seemed to 
contain a substance, called “Vagusstoff”, which in turn could lower the 
frequency of a separate frog heart (Loewi, 1921). This was a strong proof of 
chemical neurotransmission and the newly found substance, “Vagusstoff”, 
was eventually identified as acetylcholine, an important parasympathetic 
transmitter. In turn, this revolutionized the understanding of the autonomous 
nervous system and the Nobel Prize in physiology or medicine was in 1936 
awarded jointly to Henry Dale and Otto Loewi “for their discoveries relating 
to chemical transmission of nerve impulses" (Nobelstiftelsen, 1965). 
Regarding the urinary bladder, all subtypes of the G-protein coupled 
muscarinic receptors (M1-M5) have been found to be expressed in the rat 
(Creed et al., 2010; Giglio et al., 2005; Giglio et al., 2009). The muscarinic 
M3 receptor is the most important subtype for bladder contraction 
(Andersson et al., 2012; Longhurst et al., 1995; Tobin et al., 1995), and 
studies have shown that knock-out mice for this subtype express voiding 
disturbances. It has been suggested that NANC transmitters may to some 
extent compensate for loss of cholinergic function (Igawa et al., 2004; Matsui 
et al., 2000). 
Apart from having direct functional effects, acetylcholine also affects the 
purinergic system in the urinary bladder by facilitating the release of ATP in 
the urothelium. In the cat it has been demonstrated that acetylcholine not only 
releases ATP, but that it does so to a larger extent in animals suffering from 
feline IC (Birder et al., 2003). Acetylcholine has also been suggested to be 
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able to induce the release of NO and prostanoids (Andersson et al., 2008; 
Hanna-Mitchell et al., 2007). Beside its effects on muscarinic receptors in the 
urothelium, acetylcholine may also increase the sensitivity of afferent nerve 
fibers in the lower urinary tract (Iijima et al., 2007; Kullmann et al., 2008). 
Interactions between the cholinergic and purinergic systems must also be 
considered in the efferent part of the micturition arc. Parasympathetic nerve 
terminals exhibit facilitatory and inhibitory muscarinic receptors. While high 
intensity neuronal activity with relatively short endurance activates 
presynaptic muscarinic M1 receptors that facilitate transmitter release, low-
intensity activity induces inhibition via muscarinic receptors, possibly of the 
M4 subtype (D'Agostino et al., 2000; Somogyi et al., 1994; Tobin et al., 
1995; Tobin et al., 1998). Since presynaptic receptors have unspecific effects 
on the transmitter release (Ryberg et al., 2009; Tobin, 1998), and also taking 
into account the co-transmission of ATP with acetylcholine (Silinsky, 1975), 
muscarinic receptors are likely to affect the purinergic transmission. 
 
1.4.2 Nitrergic systems 
NO was first found to be endogenously formed in man some thirty years ago 
(Green et al., 1981) and a connection between this free radical gas and 
inflammation was soon suggested, as reviewed by Bredt et al. (1992). The 
amino acid L-arginine was found to be a source of endogenous NO (Hibbs et 
al., 1987) produced by enzymes collectively known as nitric oxide synthases 
(NOS) (Palmer et al., 1989). Regarding smooth muscle, NO is commonly 
regarded to produce relaxation by binding to iron in the heme part of 
guanylyl cyclase, thereby stimulating formation of cGMP which acts on 
protein kinases phosphorylating myosin, giving rise to relaxation (Bredt et 
al., 1992). In the urinary bladder, direct relaxatory effects of NO have been 
suggested (Chen et al., 1996), while questioned by other studies where 
alternative NO mechanisms, such as actions on nerves and stromal cells, have 
been implied (Fujiwara et al., 2000). 
Inducible and endothelial forms of NOS have been shown to be markedly 
increased in the urothelium of rats treated with LPS or CYP, thereby 
inducing inflammation, which suggests an important role of NO during 
pathological conditions (Andersson et al., 2008; Haleen et al., 1987; 
Longhurst et al., 1995). While acetylcholine may induce release of NO which 
counteracts the cholinergic contraction (Andersson et al., 2008; Bruns et al., 
1987; von Kugelgen, 2006), the interaction of ATP and NO in the contractile 
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response appears to be small (Muller et al., 1998; Vesela et al., 2012b). This 
is in contrast to the relaxatory purinergic response, which seems to involve 
NO (Muller et al., 1998). 
Furthermore, the purinergic and nitrergic systems may interact during 
inflammation. In endothelial cells, extracellular ATP has been shown to 
increase the production of NO through stimulation of P2X purinoceptors 
(Dunn et al., 1988). Also, opposing interactions have been identified, namely 
that NO and ATP are linked so that the ratio of ATP/NO is high in the 
overactive- but low in the underactive bladder (Soto et al., 1997).  
  
Patrik Aronsson 
 
23 
1.5 Common models for studying the 
function of the rat urinary bladder 
Traditionally, a common method to investigate functional responses to 
agonists and antagonists in the urinary bladder has been in vitro studies in 
organ baths (tissue baths). The use of this method has many advantages. It is 
a reliable and robust setup, which makes possible the examination of direct 
effects of water soluble drugs on detrusor contraction and relaxation. In many 
cases drugs are metabolized in the liver, gut or bloodstream and may produce 
confounding factors which can be disregarded when using the organ baths, 
although one must bear in mind that hydrolysis and metabolization of 
pharmacologically active substances by enzymes present in the tissue can still 
occur. Ethically, one must consider the need to euthanize the animal before 
the study, although no, or very few, experimental procedures causing 
discomfort must be performed before sacrifice. This also means that the same 
animal cannot be used in further studies, e.g. before and after treatment. 
Like many other in vitro methods studies executed in the organ bath cannot, 
however, answer questions regarding whole body physiological and 
pharmacological effects. For this purpose one must resort to in vivo studies, 
which include investigation of the micturition pattern using an awake, freely 
moving animal in a metabolism cage. Here, the composite impact of factors 
affecting the micturition pattern can be evaluated and also urine can be 
collected for further analysis. Cystometry is another method which can be 
performed in many ways, all using the same basic principle. The urinary 
bladder is filled using either a catheter through the urethra, or in some cases 
through the bladder wall. Alternatively, the animal can be injected with saline 
increasing the production of urine. Thereafter the intravesical, and sometimes 
the rectal/abdominal, pressure is recorded when experimental stimulation is 
performed. Also, the in vivo methodology enables the studies of the influence 
of the nervous system and reflexes which are not possible in vitro. 
True for these in vivo models is the fact that its greatest strength is also its 
greatest weakness; the whole body is studied, giving the response most likely 
to be of clinical interest but, at the same time, the picture can be obscured by 
the many unknown, or uncontrolled, factors affecting the results. 
Many of the studies in this thesis are based on in vitro organ bath studies. We 
did, however, identify a need to develop a novel method to further make 
possible investigations of the influence of cystitis on both efferent and 
afferent nerves, as well as the micturition reflex, at a level between in vitro 
and in vivo. The novel in situ method should render a controlled setup with 
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the possibility to measure direct effects, while having access to the 
complexity of the whole animal. A key issue was also the relative ease by 
which the new model would be comparable to previously established in vitro 
and in vivo methods. 
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1.6 Aims 
The overall aims of this thesis were to characterize the purinergic functional 
effects in the urinary bladder and to investigate the role of purines and NO in 
the development of cystitis. Furthermore, a novel method to study functional 
responses to afferent and efferent nerve stimuli in situ was developed and 
evaluated. 
 
1.6.1 Specific aims 
Several methods used in studies of the function of the rat urinary bladder 
were employed and compared in Paper I. Contractile and relaxatory 
purinergic responses were investigated in vitro in the normal rat urinary 
bladder and conclusions were drawn regarding which purinoceptor subtype(s) 
that are of importance in bladder function (Paper II). Furthermore, the 
purinergic part of the contractile response to electric field stimulation was 
characterized in both healthy rats and in ones with CYP-induced cystitis 
(Paper III). 
The study of the alterations in the inflamed rat urinary bladder, compared to 
the normal case, was further expanded using our novel in situ setup. Changes 
in contractility and reflexly evoked contractions to stretch stimulation were 
investigated in Paper IV, in which the significances of purinergic, as well as 
cholinergic, signaling were studied. 
Lastly, the roles of the purinergic, nitrergic and, to some extent, cholinergic 
systems in the development of inflammation were investigated in Paper V 
and VI, using pre-treatment with antagonists for these systems. The impact of 
the pre-treatments on not only functional response, but also on several other 
inflammation parameters, such as bladder morphology, mast cell localization 
and expression of receptors (e.g. muscarinic M5 receptors) and MIF, were 
thus investigated.  
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2 METHODS AND MATERIALS 
The methods and materials employed in the current studies are fully 
described in the respective papers. Here follows an overview of the most 
relevant aspects of the methods and materials used in this thesis. 
In all experiments male Sprague-Dawley rats were used and all studies were 
approved by the local ethics committee at the University of Gothenburg (# 8-
2006, 315-2007, 410-2008, 279-2009, 282-2010, 362-2011). 
 
2.1 In vitro organ bath studies (Paper I- III, 
V- VI) 
Rats were anesthetized and sacrificed using an overdose of carbon dioxide. 
Full thickness bladder strip preparations (approximately 2x6 mm) were cut 
from the excised urinary bladders and mounted in 25 ml organ baths 
containing Krebs solution gassed with 5% carbon dioxide and 95% oxygen, 
kept at 37oC (see Fig. 2 for a schematic representation). The specimens were 
gently stretched and left to equilibrate for 45-60 min before the experiment 
was commenced. Viability was confirmed by addition of a high potassium 
Krebs solution (124 mM) obtained by exchanging Na+ for equimolar amounts 
of K+. 
Agonists were administered cumulatively in the volume of 125 μl and the 
change in tension was recorded. Antagonists used were administered in the 
same volume and left to equilibrate for about 20 min before agonists were 
employed. When relaxations were studied the bladder strip preparations were 
pre-contracted using a 50 mM potassium Krebs solution obtained by 
exchanging Na+ for equimolar amounts of K+. Electric field stimulation was 
employed at increasing frequencies, delivered as square wave pulses with 0.8 
ms duration at supra-maximal voltage, continuously until the peak response 
was obtained. 
Removal of urothelium was in some experiments performed by filling the 
excised bladder with collagenase I (0.1% w/v in Hank's Balanced Salt 
Solution) for 30 min and then gently scraping the urothelium with a wet 
cotton swab (Paper II). 
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Figure 2. Schematic representation of the preparation and execution of in vitro 
organ bath experiments. 
 
2.2 In vivo whole bladder preparation (Paper 
I) 
Rats were anesthetized and the femoral artery and vein were catheterized in 
order to make possible blood pressure recordings and injections of 
pharmacologically active substances, respectively (see Fig. 3). Surgery was 
performed on a thermoregulated blanket to preserve body temperature and 
the trachea was cannulated to maintain a free airway. 
When the urinary bladder had been exposed, a small incision was made at the 
top and a catheter was inserted, thus enabling a bladder pressure recording. 
The change in bladder pressure to intravenous (i.v.) administration of 
agonists, i.e. methacholine and ATP, in the absence or presence of 
antagonists was then studied. Also, responses to electric nerve stimulation 
(approximately 30 s; 10-15 V square wave, 0.8 ms pulse width) were 
investigated. 
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2.3 In situ half bladder preparation (Paper I, 
IV) 
The general procedure was as described above (In vivo whole bladder 
preparation, Fig. 3). The urinary bladder was, however, exposed and split into 
two completely separated halves via a midline incision. Great care was taken 
not to damage any major blood vessels or nerves. The lower part of one of 
the two bladder halves was then fixated with ligatures to the underlying tissue 
and the upper ligature was connected to an adjustable isometric force 
transducer. The lower part of the other bladder half was also fixated and the 
upper part was used for stretching the preparation using weights of 3, 5 or, 
occasionally, 8 grams, thus evoking a stretch stimulus. Electrical and 
pharmacological stimulation was also performed in the same manner 
described previously. 
 
Figure 3. Schematic illustration of whole bladder and in situ half bladder 
preparations in the rat. Catheters were in anesthetized rats inserted in the femoral 
vein and artery (A). Thus, drug administration and blood pressure monitoring 
were made possible. Also, tracheotomy was performed (A). Subsequently, 
preparations were made for either whole bladder recordings (B), by inserting a 
dual catheter through the top of the bladder, or in situ half bladder recordings 
(C), by splitting the bladder into two separate halves where one could be 
stretched and the other was left free to contract. In both cases, preparations for 
electric nerve stimulation of the pelvic nerve were made, as depicted by the 
electrode in the bottom left corner of (B) and (C). Recording of pressure (B) or 
contractile force (C) are symbolized by the encircled arrow. From Paper I. 
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In situ half bladder preparation 
Threads were ligated at the top, sides and 
below the entrance of the pelvic nerve on each 
side of the bladder. Thereafter the bladder was 
divided into two completely separated parts 
along the midline from the top of the bladder 
all the way to the urethra (Fig. 1C). By 
performing the procedure under a microscope, 
great care was undertaken in order to avoid 
damaging the blood supply and the 
innervation. The two lower ligatures were 
fixated to the underlying tissue. The upper 
ligature from one of the bladder parts (in situ 
half bladder contractile preparation) was 
connected to an adjustable isometric force 
transducer (Linton Instrumentation, Norfolk, 
UK), while the top ligature of the other half 
bladder preparation was used for force 
application (30 mN and 50 mN). The bladder 
halves were lightly wetted during the 
experiment in order to avoid any damage to the 
tissue. A schematic overview of the surgical 
procedure is presented in Figure 1. 
 
In vivo whole bladder preparation 
In some experiments (whole bladder 
intravesical pressure examination) the urinary 
bladder pressure was measured continuously 
via a catheter (saline infusion and pressure 
recording; Fig. 1B) inserted through a small 
incision in the bladder and fixated with a 
ligature at the top of the bladder, as previously 
Figure 1: Schematic illustration of whole bladder and in situ half bladder preparations in the rat. In male anesthetized rats, 
the femoral vein and artery were catheterized to enable drug administration and blood pressure monitoring, respectively (A). 
In addition, tracheotomy was performed. The urinary bladder was then prepared for whole bladder recordings (B) or in situ 
half bladder recordings (C). In the whole bladder preparation the urinary bladder and the pelvic nerve (illustrated bottom left 
in B) were uncovered and a dual catheter was then inserted through a small incision in the top of the bladder to enable both 
saline in-flow connected to a pressure recording (encircled arrow in B), and saline out-flow (grey arrows in B). The urethra 
was ligated to enable stable basal pressure (of approximately 7 mmHg), maintained by continuous infusion of saline. In the in 
situ half bladder prep ration the urina y bladder and the pelvic nerve (illustrated in C) were uncovered, similar to the whole 
bladder preparation. Ligatures were fixed at the top, sides as well a  below the entrance of th  pelvic nerve. Th  bladder 
halves were then completely separated by an incision along the midline from the top of the bladder to the urethra, and 
ligatures were fixed to the underlying tissue. In both models the blood pressure and detrusor contraction could be recorded 
following electric stimulation of the pelvic nerve or administration of methacholine or ATP. The encircled arrow in C 
indicates tension measurement and grey arrow indicate applied stretch. The pelvic nerve could further be cut off (black 
dashed line bottom left corner of B and C) and the response of the afferent (sensory) nerve was recorded. Importantly, in the 
in situ half bladder preparation the efferent and afferent nerve response could be recorded from each of the bladder halves 
without any influence from the other, leaving the micturition reflex arc as the sole option for transmission of stimuli when 
electrically, or by stretch, activating the afference.	
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2.4 CYP- treatment (Paper III- VI) 
Experimental cystitis was induced by a single injection of CYP (100 mg/kg; 
i.p.) in combination with the analgesic buprenorphine (10 µg/kg s.c.) 60 
hours before the experiment. Controls instead received an injection of saline 
(0.9%; 1 ml/kg). 
 
2.5 Pre- treatment (Paper V- VI) 
Rats were pre-treated with intraperitoneal (i.p.) injections of purinergic 
antagonist (DPCPX, 1 mg/kg; PSB1115, 1 mg/kg or suramin, 10 mg/kg), 
muscarinic antagonist 4-DAMP (1 mg/kg), NOS inhibitor L-NAME (30 
mg/kg), or saline (1 ml/kg) as control once daily for five consecutive days 
(Fig. 4). 60 hours before the experiment the rats were treated with either CYP 
or saline (as described above). 
Figure 4. Schematic representation of the pre-treatment/treatment regimen used in 
Paper V and VI. Purinergic antagonist (suramin, DPCPX or PSB1115), muscarinic 
antagonist (4-DAMP), nitric oxide synthase inhibitor (L-NAME) or saline (as 
control) was administered by intraperitoneal injections once daily for five 
consecutive days. Sixty hours before the functional experiment treatment with either 
cyclophosphamide (CYP) or saline (as control) was administered. Adapted from 
Paper V. 
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2.6 Mast cell count (Paper V- VI) 
Sections of paraformaldehyde fixed paraffin embedded rat urinary bladders 
(4 µm) were de-paraffinized, rehydrated and stained with toluidine blue 
working solution for 2.5 min. The sections were then cleared in ethanol and 
xylene and covered using a resinous mounting medium. Toluidine blue 
positive cells in the sections, excluding the adventitia, were counted using a 
light microscope. 
 
2.7 Hematoxylin & eosin staining (Paper V) 
Four µm sections of paraformaldehyde fixed paraffin embedded bladders 
were run in a Leica Autostainer XL programmed for hematoxylin and eosin 
staining according to a standard protocol. The preparations were then 
investigated using a light microscope. 
 
2.8 Immunohistochemistry (Paper V- VI) 
Sections of paraformaldehyde fixed paraffin embedded bladders (4 µm) were 
de-paraffinized, rehydrated and treated with citrate buffer and phosphate 
buffered saline to break any protein-cross linking and non-specific staining, 
respectively. The sections were subjected to primary polyclonal antibodies 
overnight and, subsequently, secondary antibodies and rhodamine conjugated 
phalloidin. After dehydration in ethanol, sections were mounted with Prolong 
gold antifade reagent with DAPI and viewed by microscopy. Negative 
controls were treated in the same way without addition of primary antibody. 
 
2.9 Substances (Paper I- VI) 
All substances were purchased from Sigma-Aldrich, St Louis, MO, except 
for those marked with numbers as follows; 1 Tocris Bioscience, Bristol, 
United Kingdom, Stockholm, Sweden, 2 Santa Cruz Biotechnology, Santa 
Cruz, USA, 3 Molecular Probes, Eugene, USA, 4 Research Diagnostic 
Antibodies, Berkley, USA, 5 Invitrogen, Burlington, Canada, 6 Histolab, 
Gothenburg, Sweden, 7 Kemetyl, Stockholm, Sweden, 8 Apoteket Farmaci, 
and 9 Apoteket Produktion & Laboratorier AB, Gothenburg, Sweden. 
Key substances used are summarized in Tab. 1-3. 
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2.9.1 Substances acting on purinoceptors 
Adenosine, adenosine 5´-diphosphate (ADP), adenosine 5´-triphosphate 
(ATP), N,N''-1,4-butanediylbis[N'-(3-isothiocyanatophenyl)]thio urea 1 (MRS 
2578), 8-(3-chlorostyryl)caffeine (CSC), 8-cyclopentyl-1,3-dipropylxanthine 
(DPCPX), 2′-deoxy-N6-methyl adenosine 3′,5′-diphosphate diammonium salt 
(MRS 2179), α,β-methylene adenosine 5´-triphosphate (α,β-meATP), 3-(2-
oxo-2-phenylethyl)-uridine-5'-diphosphate 1 (PSB0474), pyridoxal-
phosphate-6-azophenyl-2',4'-disulphonic acid (PPADS), reactive blue 2 (RB-
2), 8-p-sulfophenyltheophylline (8-SPT), suramin, 4-(2,3,6,7-tetrahydro-2,6-
dioxo-1-propyl-1H-purin-8-yl)-benzenesulfonic acid 1 (PSB1115), 2-
thiouridine 5'-triphosphate tetrasodium salt 1 (2-ThioUTP), uridine-5´-
diphosphate (UDP), uridine-5´-triphosphate (UTP). 
 
2.9.2 Substances acting on muscarinic receptors 
Acetyl-β-methylcholine (methacholine), atropine, carbamylcholine 
(carbachol), 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP), 
methoctramine, pirenzepine. 
 
2.9.3 Substances acting on adrenoceptors 
Isoprenaline, phentolamine methansulphate, phenylephrine, propranolol. 
 
2.9.4 Substances used for immunohistochemistry 
ABC staining system sc-2018 2, Alexa Fluor 488 goat anti-rabbit IgG 3, anti-
M5 produced in rabbit 4, anti-MIF produced in rabbit, anti-P1A1 produced in 
rabbit, citric acid, goat serum, methanol, rhodamine conjugated phalloidin, 
sodium citrate tribasic dehydrate, phosphate buffered saline tablets 5, Prolong 
gold antifade reagent with DAPI 5. 
 
2.9.5 Other substances 
6-N,N-diethyl-β-γ-dibromomethylene-D-adenosine-5-triphosphate trisodium 
salt (ARL 67156 trisodium salt), CaCl2, collagenase I, cyclophosphamide 
monohydrate (CYP), dimethyl sulfoxide (DMSO), eosin 6, ethanol 7, 
glibenclamide, glucose, HCl, KCl, KH2PO4, lidocaine hydrochloride 8 
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(Xylocain®; AstraZeneca, Södertälje, Sweden), Nω-nitro-L-arginine (L-
NNA), Nω-nitro-L-arginine methyl ester (L-NAME), Meyers HTX 6, MgSO4, 
NaCl, NaHCO3, pertex 6, phosphate buffered formalin (4%) 9, toluidine blue 
O, tetrodotoxin (TTX), xylene 6. 
 
2.9.6 Anesthetics and analgesics 
Buprenorphine 8 (Temgesic®; Schering-Plough, Brussels, Belgium), 
Medetomidine 8 (Domitor®Vet; Orion Pharma, Espoo, Finland), 
Pentobarbitone 8 (Pentobarbitalnatrium vet.; APL, Stockholm, Sweden). 
 
2.10 Statistics and calculations (Paper I-VI)
 Statistical significance was determined by Student's t-test for paired or 
unpaired data. For multiple comparisons, statistical significance was 
determined by one-way analysis of variance (ANOVA) or repeated 
measurements one-way analysis of variance (MANOVA) followed by the 
Bonferroni multiple comparison test or Tukey’s HSD post hoc test. P-values 
<0.05 were regarded as statistically significant. Graphs were generated and 
parameters computed using GraphPad Prism (GraphPad Software, Inc., San 
Diego, US). Data is presented in the form of mean±S.E.M. 
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Table 1. Key substances affecting mainly P1 purinoceptors 
Name Type of substance Acting on 
receptor 
 Reference 
Adenosine Agonist P1  (Burnstock, 1978; 
Ralevic et al., 1998) 
CSC Antagonist 
 
P1A
2A
  (Jacobson et al., 1993) 
DPCPX Antagonist P1A
1
  (Bruns et al., 1987; 
Haleen et al., 1987) 
PSB1115 Antagonist 
 
P1A
2B
  (Muller et al., 1998) 
 
8-SPT Antagonist 
 
P1  (Daly et al., 1985) 
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Table 2. Key substances affecting mainly P2 purinoceptors 
Name Type of 
substance 
Acting on 
receptor 
Other 
information 
Reference 
ADP Agonist P2Y Mainly 
P2Y1, P2Y12, 
P2Y13 
(von Kugelgen, 2006) 
ATP Agonist P2X, P2Y  (Burnstock, 1978; 
Ralevic et al., 1998) 
PSB0474 Agonist P2Y
6
  (El-Tayeb et al., 
2006) 
2-thio-UTP Agonist P2Y
2
  (El-Tayeb et al., 
2006) 
UDP Agonist P2Y Mainly P2Y6 (Nicholas et al., 
1996) 
 
UTP Agonist P2Y Mainly 
P2Y
2
, P2Y
4
 
(Chen et al., 1996; 
von Kugelgen, 2006) 
 
MRS 2179 Antagonist P2Y
1
  (Boyer et al., 1998) 
MRS 2578 Antagonist P2Y
6
  (Mamedova et al., 
2004) 
 
PPADS Antagonist P2 Not P2X4, 
P2X6 
(Ralevic et al., 1998; 
Soto et al., 1997; 
Ziganshin et al., 
1993) 
 
RB-2 Antagonist P2  (Nakazawa et al., 
1991; Ralevic et al., 
1998) 
 
Suramin Antagonist P2 Not P2Y4. 
Has ecto-
nucleotidase 
inhibiting 
properties 
(Crack et al., 1994; 
Dunn et al., 1988; 
Soto et al., 1997) 
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α,β-meATP Desensitizer 
/Agonist 
P2X1, 
P2X3 
Generally 
not P2Y. 
Functionally 
used as 
antagonist 
(Ralevic et al., 1998) 
ARL 67156 Ectonucleo-
tidase 
inhibitor 
 - Blocks 
break-down 
of ATP/UTP 
(Crack et al., 1995) 
Gliben-
clamide 
Antagonist  - Blocks ATP 
sensitive K-
channels 
(Gribble et al., 2003) 
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Table 3. Key substances affecting cholinergic, nitrergic and adrenergic 
receptors 
Name Type of 
substance 
Acting on 
receptor 
Other 
information 
Reference 
Carbachol Agonist Cholinergic 
receptors 
Both 
muscarinic 
and nicotinic 
(Goodman et al., 
2001; Sellers et 
al., 2012) 
Methacholine Agonist Muscarinic 
M1-M5 
Only minor 
nicotinic 
activity 
(Goodman et al., 
2001) 
4-DAMP Antagonist Muscarinic 
M1/M3/M5 
Possibly 
most 
effective at 
M1 
(Eglen et al., 
2000) 
Atropine Antagonist Muscarinic 
M1-M5 
 (Goodman et al., 
2001; Hegde et 
al., 1997) 
 
Methoctramine Antagonist Muscarinic M2 > other 
muscarinic 
subtypes 
(Melchiorre et 
al., 1987; Wess 
et al., 1988) 
Pirenzepine Antagonist Muscarinic M1 > other 
muscarinic 
subtypes 
(Caulfield, 
1993) 
 
 
     
L-NAME NOS 
inhibitor 
 - Is rapidly 
metabolized 
to L-NNA 
(Brouillet et al., 
1995; Pfeiffer et 
al., 1996) 
 
L-NNA  NOS 
inhibitor 
 - More potent 
& less water 
soluble than 
L-NAME 
(Dwyer et al., 
1991; 
Kopincova et 
al., 2012) 
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Isoprenaline Agonist β-
adrenoceptors 
Affects all β-
subtypes 
(Emorine et al., 
1994; Lotti et 
al., 1982) 
 
Phenylephrine  Agonist α1-
adrenoceptors 
 (Minneman et 
al., 1994) 
Phentolamine Antagonist α-
adrenoceptors 
Similar 
affinity for 
α1 and α2 
(Goodman et al., 
2001) 
 
 
Propranolol Antagonist β-
adrenoceptors 
More 
effective at 
β1 and β2 
than β3 
(Cohen et al., 
1995; Cohen et 
al., 1980) 
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3 RESULTS AND DISCUSSION 
The primary endpoint of all medical experiments is to find the underlying 
causes for morbidity. The extrapolation of preclinical findings requires at 
some stage in vivo experiments to be performed in order to gain knowledge 
needed to verify the significance of other experimental findings. 
However, functional responses in the urinary bladder can be studied in 
several ways, all with their respective pros and cons. Among the most 
common approaches are in vitro examinations of contractions and relaxations 
using bladder strip organ bath preparations, which have been used in Paper I-
III, V-VI. This method is considered to generate robust data and allows for 
the study of selected receptors or systems by administration of agonists, 
antagonists or other substances such as enzyme inhibitors or, alternatively, 
electric field stimulation. Also, concentrations of pharmacologically active 
substances being toxic, or causing unwanted side-effects, to a living animal 
can be used, thereby obtaining concentration-response data allowing for 
mathematical assessment. 
This in vitro technique does, however, not necessarily provide all information 
required to fully understand the complex nature of the living organism. It is, 
for instance, in isolated bladder strips not possible to look at reflexes, or other 
involvement of the central nervous system, changes in blood pressure, 
hormonal factors etc. Therefore, in vivo studies on changes in intravesical 
pressure in anesthetized animals, as have been employed in Paper I, are 
usually performed. This methodology, while adding more complexity to the 
performance and interpretation of the study, makes possible investigations of 
the impact of pharmacologically active substances or electric nerve 
stimulation on the bladder pressure, taking into account many of the intricate 
systems involved in the functional regulation of the lower urinary tract. 
Alternatively, in order to study the wake, free-moving animal, we have 
previously used metabolism cages (Andersson et al., 2011). While this 
methodology may arguably present the “true” nature of the systems studied, 
it also adds further complexity, compensating mechanisms and confounding 
factors, such as water intake etc., to take into consideration, which may 
obstruct the possibility to draw conclusions from such studies. 
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3.1 Experimental setups for functional 
studies 
In this thesis, the in vitro organ bath preparation and in vivo bladder pressure 
studies on anesthetized rats have been compared to a third, novel in situ half 
bladder setup, used in Paper I and IV. This novel model allows for studies of 
the stretch-evoked micturition reflex arc, while at the same time make 
possible the use of pharmacological stimulation and also afferent and efferent 
nerve stimulation. The three functional methodologies mentioned were 
compared based on contractile responses to administration of agonists and 
electricity. 
 
3.1.1 Comparisons of response to agonists 
The respective responses to the administration of agonists were studied in the 
aforementioned three experimental setups. Since the contractile responses are 
measured in different units in the whole bladder preparation (mmHg) 
compared to the in situ half bladder preparation and in vitro organ bath setup 
(mN), the magnitude of the figures will of course differ. Important 
conclusions can, however, be drawn from analyzing the response patterns. 
In the whole bladder preparation (Paper I), the contractions to methacholine 
(5 µg/kg) and ATP (100 µg/kg) were of similar sizes (7.3±1.7 and 7.9±2.0 
mmHg, respectively, Fig. 5). Comparable responses were found in the novel 
in situ half bladder experimental setup, where the same doses as above of 
agonists evoked contractions of 7.0±2.3 mN (methacholine) and 8.9±2.0 mN 
(ATP). The maximal contractile response seemed to be reached at higher 
doses of methacholine in the whole bladder model, compared to in the in situ 
setup. This may possibly be due to the difference in muscle organization, 
where the whole bladder can contract in the in vivo setup whereas only 
longitudinal contractions are possible in situ (Gabella et al., 1990). 
On a molar basis, the differences in contraction between methacholine and 
ATP were rather small in the in situ setup, with 18 nmol/kg ATP yielding a 
contraction of a magnitude between those evoked by 10 and 26 nmol/kg 
methacholine (4.0 compared to 2.8 and 7.0 mN, respectively). Atropine (1 
mg/kg) abolished contractions to methacholine and reduced ATP-evoked 
contractions (100 µg/kg) to 1.7±0.2 mN. 
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Figure 5. Mean contractile responses to methacholine (A) and ATP (B) in the whole 
bladder in vivo model, the in situ half bladder setup and the organ bath in vitro 
method. * denotes p<0.05 compared to lowest agonist dose. Functional response is 
measured in mmHg in the whole bladder model and in mN in the half bladder setup 
and in vitro studies. n=4-9, vertical bars represent the S.E.M. Adapted from Paper I. 
 
Interestingly, administration of methacholine and ATP to the in vitro organ 
bath preparation (Paper I) evoked much larger contractions in the former case 
than did ATP (33.0±2.1 mN to 0.1 mM methacholine and 7.3±1.4 mN to 5 
mM ATP). The relation between the ATP- and methacholine-evoked 
responses thus varied under different conditions. The discrepancies elucidate 
the composite effects in the response in the whole animal, which may enable 
synergistic, as well as counteracting, influences, by factors such as blood 
flow reductions etc. This underlines the complexity of possible interactions 
previously shown, namely that the muscarinic M2 receptor plays a inhibitory 
role on purine-evoked contractions in vitro (Giglio et al., 2001) as well as 
recent findings of possible negative interactions between P2X purinoceptors 
and cholinergic receptors in rat muscle cells (Heppner et al., 2009; Jenes et 
al., 2012). Also, an ATP-induced release of ATP has been described in 
several types of tissue (Bodin et al., 1996; Sperlagh et al., 1991), including 
the urinary bladder (Sun et al., 2006). Previous studies have also described an 
ATP-induced release of acetylcholine (Northway et al., 1980) in the dog 
intestine, even though others have found an inhibitory relationship (Barajas-
Lopez et al., 1995), which puts further emphasis on the complex nature of the 
interactions of these systems. 
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3.1.2 Comparisons of response to electrical 
stimulation 
Electrical efferent stimulation of the parasympathetic pelvic nerve evoked 
similar, but nevertheless slightly different, patterns in the in vivo and in situ 
preparations (Paper I, Fig. 6). The former setup displayed its peak response at 
10-20 Hz (13.3±1.2 mmHg at 20 Hz), whereas the latter, in situ, preparation 
showed no absolute maximum to efferent simulation, although occasional 
observations showed no further increase above 40 Hz (19.8±3.6 mN at 40 
Hz). In vitro, the maximal response to electric field stimulation was observed 
at 40 Hz (Paper II and III). 
Also the contractile responses to afferent electrical stimulation showed great 
resemblance in vivo and in situ (Paper I). Maximal responses were detected 
around 40 Hz (6.7±0.7 mmHg in vivo and 4.4±0.5 mN in situ), even though 
no absolute maximum contraction could be determined in the whole bladder 
preparation, whereas it seemed to occur at 20-40 Hz in the in situ half bladder 
preparation. Additional pentobarbitone or transection of the pelvic nerve on 
the contralateral side abolished the functional response to afferent 
stimulation. 
Furthermore, the threshold frequencies were similar in the in vivo and in situ 
setups studied to both efferent (<2 Hz) and afferent electrical nerve 
stimulation (5-10 Hz, Paper I). In vitro, the electric field stimulation 
threshold frequency was found to be <2 Hz (Paper II and III). 
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Figure 6. Representative recordings of electric stimulation of efferent (upper row) 
and afferent (bottom row) pelvic nerve fibers in the conventional in vivo whole 
bladder model (A, D) and in situ half bladder model (B, E). Mean contractions to 2-
40 Hz are also presented (C, F). Functional response is measured in mmHg in the 
whole bladder model and in mN in the half bladder setup. n=4-5, vertical bars 
represent the S.E.M. From Paper I. 
 
3.1.3 Functional response to mechanical stretch 
Mechanical stretch of 30, 50 or 80 mN to one half of the bladder caused 
contractions on the contralateral side that were close to the threshold in the 
first case, and well above in the following (Paper I and IV), where the 
responses to 50 and 80 mN stretch stimulation were of similar magnitudes 
(Paper IV). Furthermore, the size of the stretch-evoked response was in the 
same order as the contraction to afferent nerve stimulation (5.4±1.4 and 
4.4±0.5 mN, respectively, in Paper I). The response to these stimulations was 
found to be well preserved over time (up to 60 min) and could be abolished 
by administration of additional pentobarbitone or by cutting the contralateral 
pelvic nerve. 
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3.1.4 Conclusion of experimental setup 
comparisons 
A large degree of similarity between the novel in situ half bladder setup and, 
predominantly, the traditional in vivo urinary bladder pressure model was 
seen. Overall, the agonist- and EFS-evoked responses of the various models 
studied correlated well and were found to be comparable. The major 
difference observed was compared to the in vitro organ bath setup, where the 
purinergic response was much smaller compared to the cholinergic, which 
indicates a complex interaction between purinergic and cholinergic systems. 
The novel method was proven to be reliable for a rather long period of time 
(at least one hour) and to yield reproducible data. Furthermore, it offers the 
significant advantage of making possible the study of stretch-induced 
contractile responses of the urinary bladder, mediated via the reflex arc, a 
feature which is likely altered during cystitis (see Paper IV). Afferent 
mechanisms and stretch sensitivity have previously been studied. In those 
experiments, however, the focus has often been on neuronal activity, rather 
than on the functional outcome of this parameter, i.e. bladder contraction 
(Ishii et al., 2012; Zagorodnyuk et al., 2007). Alternatively, micturitions have 
been allowed, producing spikes in bladder pressure depending on the level of 
bladder filling (Mallory et al., 1989; Yu et al., 2013). The novel in situ setup 
provides an alternative to this, enabling graded measurements of bladder 
contraction and studies of lateral cross-transmission without interference of 
the volume of bladder contents. 
It may be argued that the afferent stimulation evoked substantially smaller 
contractions than did the efferent stimulation. However, one ought to bear in 
mind that the responses were measured on the contralateral side to the nerve 
being stimulated, and that only one side was stimulated. It has previously 
been demonstrated in the cat that contralateral neuronal activity occurs, 
however with less intensity than in the ipsilateral side (Mazieres et al., 1998). 
Also, in the normal micturition reflex the whole bladder is stretched, and by 
that more impulses may reach the central nervous system. 
By studying the stretch-evoked contralateral contractions, one can gain 
important knowledge of this physiologically important mechanism. Also, the 
risk of any antidromic transmitter release is markedly reduced by using the 
novel setup for stretch-stimulation instead of electrical nerve stimulation. 
Additionally, compared to the in vivo whole bladder model, one does not 
have to take into consideration the confounding factors of saline in- and 
outflow or the extent of bladder filling. Also, it would, in future experiments, 
be possible to manipulate the half of the bladder being stretched, e.g. by 
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removal of the urothelium, while keeping the contralateral half intact, thereby 
avoiding to cause any damage on the contractile half. Furthermore, 
experiments could be performed, in which the direct functional role of the 
different types of stretch receptors can be characterized (Zagorodnyuk et al., 
2007). 
Thus, the novel in situ half bladder method provides an important 
complement to the well-established in vivo and in vitro methods presented. 
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3.2 Purinergic in vitro functional effects in 
the normal urinary bladder 
 
3.2.1 Agonist- evoked responses 
In contrast to the EFS-evoked response (see next section), aiming to activate 
transmitter release from nerve fibers, contractions and relaxations to 
administration of exogenous ATP were not affected by addition of TTX (1.25 
µM, Paper II), suggesting the purinergic response to be mediated through 
post-synaptic receptors. 
ATP gave rise to more pronounced bladder contractions than did ADP, UTP 
and UDP (Fig. 7A), which were employed in order to characterize the 
involvement of different P2 purinoceptor subtypes. The relaxatory responses 
to the nucleotides were, however, clearly divided into two separate groups, 
where ADP=ATP > UDP=UTP (Fig. 7B). At 300 µM the relaxations to ADP 
and ATP were -71±12 and -68±9%, respectively, whereas the relaxations to 
UDP and UTP were -35±5 and -33±3%, respectively. 
 
Figure 7. Mean contractions (A; n=5-12) and relaxations (B; n=6-9) in urinary 
bladder strip preparations to the purinergic agonists ADP (), ATP (), UDP () 
and UTP (). Vertical bars represent the S.E.M. From Paper II. 
 
Addition of the ectonucleotidase inhibitor ARL67156 did, in Paper II, not 
seem to cause any major over-all alterations in the relaxatory response to 
ATP or UTP. Interestingly, the relaxations to the lowest dose (1 µM) of both 
ATP and UTP were attenuated (from -19 to -2% and -7 to -2% p<0.05, 
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respectively), suggesting the break-down into di- or monophosphates to be of 
importance to the relaxatory response. Further studies, perhaps using higher 
doses of the ectonucleotidase inhibitor, should be performed to investigate if 
this is accurate. 
The P2 purinoceptor antagonist PPADS concentration-dependently (0.3-30 
µM; Paper II) attenuated the ATP-evoked contractions whereas the P2 
purinoceptor antagonist suramin did not have any significant effect (Fig. 8). 
Furthermore, the unselective P1 purinoceptor antagonist 8-SPT, the P1A2A 
purinoceptor antagonist CSC and the unselective P2Y antagonist RB-2 did 
not affect the contractile response. One ought to bear in mind that PPADS, 
and perhaps to an even greater extent suramin, are “dirty drugs” and thus may 
exert a number of actions, as reviewed by Ralevic et al. (1998) and Soto et al. 
(1997). However, taking into account the fact that PPADS and suramin do 
not have identical affinities for the P2X1 purinoceptor, together with the 
results from the studies with α,β-meATP may support the conclusion that 
P2X1 is the purinoceptor mainly, but not solely, responsible for the 
purinergic contraction of the urinary bladder (Kennedy et al., 2007). 
 
Figure 8. ATP-evoked contractions in the absence of antagonist (basal) and in the 
presence of increasing concentrations of PPADS (A) or suramin (B). n=5-6, 
vertical bars represent the S.E.M. *p<0.05 vs. basal. From Paper II. 
 
The general P1 purinoceptor antagonist (8-SPT) did, however, lower the 
relaxatory response to ATP, which was unaffected by the P1A2A purinoceptor 
antagonist CSC, as well as by suramin and PPADS. To further investigate the 
relaxatory role of the P1 receptors, adenosine was administered, which 
caused relaxations that could to some extent be blocked by the P1A2B 
purinoceptor antagonist PSB1115. Thus, purinergic relaxation seems to be, at 
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least partly, depending on the P1A2B, but not the P1A2A, purinoceptor. These 
findings in Paper II were confirmed, and the understanding expanded, in one 
of our later studies, where the relaxatory response to a standard dose of 
adenosine (50 µM) was investigated in the presence of various antagonists 
(Vesela et al., 2011). In the normal rat (but not in animals with CYP-induced 
cystitis), the P1A1 purinoceptor antagonist DPCPX was found to decrease the 
major part of the relaxatory response to adenosine, thus the P1A1 
purinoceptor was suggested to be responsible for this relaxation. 
Furthermore, another selective P1A2A purinoceptor antagonist (SCH 58261 
instead of CSC) was administered, but also failed to affect the adenosine-
evoked relaxation, whereas the P1A3 purinoceptors, in contrast to the other 
P1 purinoceptors, were found to inhibit the relaxatory responses to adenosine. 
It is thus likely that the DPCPX-resistant part of the relaxation is due to the 
P1A2B purinoceptor. 
 
 
Figure 9. Mean relaxations/contractions to UTP (0.3 mM) in the absence or 
presence of increasing concentrations of PPADS. n=5, vertical bars represent the 
S.E.M. * denotes p<0.05 compared to absence of antagonist. Lower panel shows 
representative recordings of relaxations/contractions to UTP (0.3 mM) in the 
absence (0) or presence of PPADS (0.3-30 µM). From Paper II. 
 
In Paper II the relaxatory response to UDP was reduced by the addition of 
suramin and tended to be blocked by PPADS. The relaxation was not affected 
by the P2Y6 purinoceptor antagonist MRS 2578. On the other hand, 
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relaxations to UTP were reduced by PPADS (but not suramin), which even 
caused contractions, instead of relaxations, at the highest antagonist 
concentration (Fig. 9). Relaxations to ATP and ADP were unaffected by both 
PPADS and suramin. 
This further strengthens the hypothesis that relaxations to ADP/ATP and 
UDP/UTP are mediated via two separate (groups of) receptors in the rat 
urinary bladder. Based on the data presented, one cannot be certain which 
receptor subtype that is responsible for the relaxations to UDP/UTP, but 
judged by the pharmacological profile of UDP/UTP, the P2Y purinoceptor 
family is most likely involved. One candidate may be a P2Y6-like 
purinoceptor (as suggested to be important in other tissues). Possibly, the 
P2Y4-purinoceptor may be involved as well. 
Regarding urothelium-denuded full thickness urinary bladder strip 
preparations investigated in Paper II, the contraction to the muscarinic 
receptor agonist carbachol was unaffected, whereas the ATP-evoked 
relaxatory response was attenuated by removal of the urothelium. This 
indicates that the urothelium has a relaxatory role, to some extent affecting 
the relaxatory response to ATP, which further strengthens the theory of the 
urothelium being important in bladder signaling (Ferguson et al., 1997). 
 
3.2.2 Electric field stimulation- evoked responses 
Frequency-dependent contractions to electric field stimulation were obtained, 
showing maximal contraction at 40 Hz. These contractions were totally 
abolished by the addition of TTX (Paper II) or lidocaine (Paper III), 
demonstrating that the effect seen was strictly due to neuronal release of 
transmitter and not because of any direct effect on the smooth muscle. 
Frequency-dependent contractions can be sub-divided into the fast, transient 
“phasic” phase and the longer lasting “tonic” phase (Maggi et al., 1985). The 
phasic phase is to a large extent atropine-resistant (Paper III, Fig. 10A) but 
was found to be attenuated by the repeated addition of the P2X1/P2X3 
desensitizer α,β-meATP (10 µM), with no further decrease caused by the 
general P2 antagonist PPADS (Paper II, Fig. 10C). In contrast, the tonic 
phase was found to be sensitive to atropine (Paper III, Fig. 10B), which 
completely abolished the tonic component of the EFS-evoked response when 
added after addition of α,β-meATP and PPADS (Paper II, Fig. 10D). 
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Interestingly, the tonic component seemed to be unaffected by atropine at low 
frequencies (<5 Hz) but lowered by purinergic blockade, whereas the 
opposite was seen at higher frequencies (Paper II and III, Fig. 10B and Fig. 
10D), suggesting a relatively large purinergic involvement at low 
frequencies. The effects of atropine and α,β-meATP in the normal (i.e. not 
inflamed) bladder are in line with previous studies in the guinea-pig (Brading 
et al., 1989; Kasakov et al., 1982), and also in the rat (Brading et al., 1990), 
where this blockade abolished the EFS-evoked contractile response. The 
phasic part of the contraction, however, could at higher frequencies not 
currently be abolished by cholinergic and purinergic antagonists suggesting 
other NANC transmitters to be of some importance in the response to EFS, 
which has been previously indicated (Luheshi et al., 1990).  
 
Figure 10. Mean phasic (A, C) and tonic (B, D) contractile responses to electrical 
field stimulation (1-60 Hz). The upper row (A, B) shows responses in the absence () 
and presence of atropine (; 5 µM). The lower row (C, D) depicts contractions in 
the absence () and presence of the P2X1/P2X3 desensitizer α-βmeATP (; 10 µM, 
repeated 3-4 times), α-βmeATP (10 µM, repeated 3-4 times) and the P2 purinoceptor 
antagonist PPADS (; 30 µM) and α-βmeATP (10 µM, repeated 3-4 times), PPADS 
(30 µM) and the muscarinic receptor antagonist atropine (; 5 µM). n = 8-10, 
vertical bars represent the S.E.M. Adapted from Paper II and III. 
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This confirms the notion that purinergic transmitters are of the greatest 
importance in the rapid phasic contraction, whereas the cholinergic system is 
mainly responsible for the tonic component of the contraction (Fig. 11). In 
analogy, further studies (Paper III) revealed that the muscarinic M1/M3/M5-
receptor antagonist 4-DAMP caused a concentration-dependent decrease in 
tonic contraction, while affecting the phasic contraction only to a minor 
extent. In this context it may be worth considering that the cholinergic 
bladder response may include urothelial inhibitory factor(s) (Andersson et al., 
2012; Fovaeus et al., 1999; Giglio et al., 2008) that may partly mask the real 
reduction of the muscarinic M3 receptor mediated contraction. Furthermore, 
since the composite EFS-evoked response was found to be composed of both 
cholinergic and purinergic responses, the adrenergic system was also 
investigated by the administration of the adrenergic antagonists propranolol 
(1 µM) and phentolamine (1 µM) in the presence of atropine. This did, 
however, not affect the atropine-resistant EFS-response (Paper III), 
suggesting that the non-cholinergic contractile response to EFS does not 
depend on adrenergic transmission to any large extent. 
Figure 11. Schematic representation of possible interplay between purinergic (black 
dotted line) and cholinergic (black solid line) responses to electric field stimulation. 
Tentatively, the purinergic part of the contraction constitutes a swift initial 
contraction, while the onset of the cholinergic part of the response is slower, but the 
response longer lasting. The composite response (grey thick line, corresponding to 
that of electric field stimulation at 2 Hz) consists of both these contractions, where 
the purinergic response is of greater importance in the initial, phasic, phase and the 
cholinergic in the tonic phase. 
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In separate experiments, the effect of the ectonucleotidase-inhibitor 
ARL67156 on the EFS-evoked contraction was investigated (Paper II). While 
the tonic component of the response was unchanged, the phasic component 
was decreased by 23-53% (p<0.01-0.05, n=7). This is in contrast to previous 
studies in other species (Westfall et al., 1997), and this discrepancy may 
perhaps be due to lowered stimulation of purinoceptors sensitive to 
metabolites of ATP (i.e. ADP, AMP or, possibly, adenosine) involved in 
mediation of contractile response or pre-synaptic positive feedback of 
transmitter release. In this context it is worth considering the rather common 
occurrence of for instance P1A1 purinoceptors known to modulate transmitter 
release in the central nervous system (Van Dort et al., 2009), in the 
neuromuscular junction (Veggetti et al., 2008) and also suggested in the 
urinary bladder (Fry et al., 2004). This could possibly provide an explanation 
to the opposite responses seen in Paper II. 
 
3.2.3 Conclusion of purinergic in vitro functional 
effects in the normal urinary bladder 
A number of different purinoceptor subtypes are expressed in the lower 
urinary tract. Since their effects vary markedly, the functional response is 
likely the composite result from synergistic, as well as counteracting, effects. 
The current results suggest, in accordance with other studies (Kennedy et al., 
2007), the purinergic contractions to be mediated mainly by the P2X1 
purinoceptor. While ATP evoked larger contractions than the other agonists 
used, the relaxatory response was divided into two groups, where ADP and 
ATP evoked larger relaxations than UDP and UTP. Based on the 
pharmacological profile of the latter two, and the fact that the relaxation was 
sensitive to P2 purinoceptor antagonism, purinoceptors of the P2Y family are 
likely to play a relaxatory role in the rat urinary bladder. 
The picture gets even more complicated by the possible interactions with 
other transmitter systems, as underlined in the studies in different 
experimental setups (Paper I) where, for instance, ATP evoked markedly 
larger responses compared to methacholine, in situ than in vitro. Also, these 
responses to ATP were reduced by atropine. In the canine intestine, ATP has 
previously been shown to cause neuronal release of acetylcholine (Northway 
et al., 1980). In unpublished experiments in the rat, the removal of the 
urothelium did not affect the magnitude of the ATP response, thus ATP-
evoked release of acetylcholine from rat bladder neurons seems feasible. In 
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vitro this did not seem to occur since the ATP response was much smaller 
than the cholinergic and since TTX did not affect the response.  
Adenosine was presently shown to play a relaxatory role in the function of 
the urinary bladder, with the P1A2B purinoceptor subtype being partly 
responsible for the purinergic relaxation. 
Furthermore, the phases of the EFS-evoked contraction were studied, and the 
initial, rapid phasic part, as well as contractile responses to low frequencies, 
was found to be largely mediated by the purinergic system, whereas the long-
lasting tonic part was affected to a much greater extent by atropine and other 
cholinergic antagonists. The results also indicate that the phasic part of the 
contraction to some extent depends on other NANC transmitters than the 
purinergic. Thus, purinergic and cholinergic systems interact in a number of 
ways.  
  
Patrik Aronsson 
 
53 
3.3 Changes in cyclophosphamide- induced 
cystitis 
Macroscopically, bladders from CYP-treated rats were clearly affected, 
showing reddening and thickening of the bladder wall (Paper III-VI). 
Regarding general contractility, the contractile response by KCl (124 mM) 
was larger in control than in inflamed bladder strips. Data normalized to the 
maximal KCl response show twice the contractile response per mg in control 
strips compared to preparations from rats with CYP-induced cystitis (1.9±0.2 
and 0.9±0.1 mN/mg, respectively, p<0.001, Paper III). 
 
3.3.1 Changes in response to electric field 
stimulation 
Contractile responses to EFS (1-60 Hz, Fig. 12) were the same in control and 
inflamed strip preparations (100±5 and 101±7% at 40 Hz) when normalized 
by the maximal contraction to KCl. This indicates that the reduction in 
response observed in inflamed bladder strip preparations largely depends on a 
hampered muscle contractile capacity. 
 
Figure 12. Representative recordings of contractions evoked by electrical field 
stimulation (1-60 Hz) in urinary bladder strip preparations from controls (first row) 
and rats with CYP-induced cystitis (60 hours before the experiment; second row). 
Horizontal bars below the recordings indicate stimulation periods. 
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The time to maximal EFS-evoked contraction was similar in control and 
inflamed strips, with the time to peak response increasing with frequency 
from 7-8 sec at 1 Hz to 14-16 sec at 10 Hz (Paper III). However, the 
contractile velocity (expressed in the vector-like form of “% of maximal 
basal response per sec”) increased with higher frequencies, probably due to 
the much higher maximal response at these frequencies. The increase in time 
to maximal contractile response, in contrast to contractile velocity, with 
frequency may well, however, be due to a combination of the increased 
maximal contraction and that the fast purinergic transmission may be more 
prominent at lower frequencies (<5 Hz). 
The relative atropine-sensitivity of the rapid “phasic” phase, previously 
described in this thesis, was similar in both normal and inflamed strip 
preparations. However, the muscarinic antagonists used were shown to be 
less potent in inhibiting the tonic component in inflamed bladders, compared 
to controls (Paper III), suggesting the NANC efferent contractile transmission 
to be of greater importance in the tonic contraction in cystitis than in the 
normal case. However, as indicated in Fig. 13, the atropine-resistant part of 
the EFS-evoked response may not necessarily only reflect contractions 
evoked by ATP. Other NANC transmitters, such as tachykinins also 
contribute, see Vesela (2012a). Nevertheless, taken together this shows that 
the normalization of contractions to potassium-evoked responses do not show 
the complete picture. Namely, in CYP-induced cystitis, compensatory NANC 
mechanisms may mask the reduced cholinergic response. Also, direct 
comparisons of the relative size of the different parts of the contraction, e.g. 
comparing the magnitude of the NANC part under different conditions, have 
proven to be hard to perform. Positive and negative interactions on pre- and 
post-synaptic levels may occur (Giglio et al., 2001; Tobin et al., 1995; Tobin 
et al., 1998). For instance, if the cholinergic part of the contraction is 
reduced, the NANC part may increase because of less negative feed-back. 
Further studies were carried out (in Paper III) to investigate the differences in 
the atropine-resistant part of the EFS-evoked contraction between normal and 
inflamed bladder strip preparations. The fact that this part was, to a large 
extent, sensitive to the addition of α,β-meATP (10 µM; applied 3-4 times), 
suggests an involvement of P2X1 purinoceptors (Fig. 13). This purinergic 
contraction was not further decreased by the subsequent addition of suramin, 
and tended to be somewhat larger in the controls, compared to preparations 
from CYP-treated rats, as indicated in gray in the figure. 
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Figure 13. Contractile responses to electrical field stimulation (1-60 Hz) in urinary 
bladder strip preparations from control rats (A) and rats with CYP-induced cystitis 
(B). Mean responses in the absence (), and in the presence of atropine, propranolol 
and phentolamine (; 5 µM, 1 µM and 1 µM, respectively) and the subsequent 
additional administration of α-βmeATP (; 10 µM, repeated 3-4 times) and α-
βmeATP and suramin (; 10 µM, repeated 3-4 times and 0.1 mM, respectively). The 
gray area represents part of the response suggested to be mediated by P2X1 
purinoceptors. n=7 in both groups, vertical bars represent the S.E.M. Adapted from 
Paper III. 
 
Further modeling of the raw data used in Paper III combined with previously 
unpublished data of the effect of PPADS more clearly show the EFS-evoked 
contractions to be smaller in cystitis than in control (Tab. 4). Also, it is 
evident that the addition of PPADS (30 µM) significantly inhibits the 
composite (i.e. not separated into phasic and tonic) contraction to EFS-
stimulation in bladder strip preparations from normal, but not CYP-treated, 
rats, as indicated by the large difference in EF50 between the normal, but not 
inflamed, preparations. 
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Table 4. Modeling of in vitro EFS-evoked contractions in normal and 
inflamed urinary bladder strip preparations. Pharmacodynamic modeling 
was performed by applying built-in models for nonlinear regression (curve fit 
according to either agonist vs. response (variable slope and four 
parameters), bell-shaped or biphasic concentration-response curves). Emax 
and Hill coefficients (nH) were generated. In the model fitting procedure, 
comparisons were based on visual inspection of observed vs. predicted plots, 
value of the objective function and assessment of parameter correlation 
precision (R2). Numbers within parenthesis are modeled Emax values. The 
data used for modeling are previously presented in percentage values in Fig. 
4 in Paper III, except for the data regarding PPADS which is unpublished 
material from pilot experiments. 
 
 Emax (mN) EF50 (Hz) nH n R2 
Normal 
 
16±2 4.8 1.5 10 0.79 
CYP 
 
10±2 5.5 1.1 8 0.49 
Normal with atropine (5 µM) 
 
7±1 3.7 1.2 10 0.52 
CYP with atropine (5 µM) 
 
5±1 6.8 0.8 8 0.39 
Normal with PPADS (30 µM) 
 
(18±2) 7.0 1.1 6 0.67 
CYP with PPADS (30 µM) 
 
(8±1) 6.2 1.0 6 0.81 
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3.3.2 Cyclophosphamide- induced cystitis in the in 
situ experimental setup 
In the in situ half bladder preparation (Paper IV) the contractions to 
methacholine were lowered in rats with CYP-induced cystitis, compared to 
control rats (2.1±0.2 and 3.1±0.5 mN, respectively to 5µg/kg methacholine). 
The response to ATP was, however, not significantly altered (Fig. 14). 
Transection of the pelvic nerve did not affect the exogenously administered 
agonist-evoked contractions. Interestingly, addition of atropine did not only 
abolish the contraction to methacholine, but did also attenuate the response to 
ATP in both normal and CYP-treated rats.  
 
Figure 14. Mean contractile responses to intravenously administered methacholine 
(A) and ATP (B) in control (normal) rats and rats with cyclophosphamide-induced 
cystitis (CYP), using the novel in situ half bladder setup. n=5-8, vertical bars 
represent the S.E.M. * denotes p<0.05. From Paper IV. 
 
The contractile response to electric nerve stimulation was lowered in CYP-
treated rats. Even though no absolute maximum was observed, a plateau 
seemed to be reached at around 40 Hz, which is consistent with what is 
reported in Paper I. The reduction in contractile response was evident at 
frequencies above 5 Hz, and at 40 Hz the maximal contraction was reduced 
by approximately 50% in the CYP-treated animals.  
In contrast to the methacholine- and electric nerve stimulation-evoked 
responses which were reduced, and the ATP-evoked contraction which was 
unchanged, the contractile response to stretch-stimulation was significantly 
elevated in CYP-treated rats. Stretch of one bladder half with 50 or 80 mN 
produced statistically significant increases in contralateral bladder half 
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contraction (Fig. 15), and application of 30 mN showed a convincing 
tendency of doing the same. 
 
Figure 15. Mean in situ contractile responses to contralateral stretch-stimulation (A) 
in control (normal) rats and rats with cyclophosphamide-induced cystitis (CYP). 
n=6, vertical bars represent the S.E.M. * denotes p<0.05 and ** denotes p<0.01. 
Also shown are representative recordings of contralateral stretch-evoked (50 mN) in 
situ bladder half contractions in normal (B) and CYP-treated (C) rats. Horizontal 
bars represent duration of stretch-stimulation. Adapted from Paper IV. 
 
In separate experiments, where the aforementioned observations were 
reproduced, atropine (1 mg/kg i.v.) reduced the stretch-induced contralateral 
contractions by about 50% in control rats and by about 75% in rats with 
CYP-induced cystitis. The subsequent addition of PPADS (2 mg/kg i.v.) 
lowered the contractions by a total of about 80% in the normal rats and >90% 
in CYP-treated rats (Fig. 16). Noteworthy is that stretch-induced contraction, 
by application of 30 mN, was not affected to any large extent by atropine, 
while the subsequent addition of PPADS almost completely removed the 
reflexly-evoked contractions in both normal and CYP-treated rats. This 
indicates that this “low-intensity stimulation” to a larger extent is mediated 
by purinergic transmission and that the part of the response being mediated 
by cholinergic receptors requires a more powerful stimulus. 
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Figure 16. Mean in situ contractions to contralateral bladder half stretch-stimulation 
(30-80 mN) in control (normal; A) rats and rats with cyclophosphamide-induced 
cystitis (CYP-treated; B) in the absence and presence of atropine (1 mg/kg) and the 
subsequent (following atropine) administration of PPADS (2 mg/kg) n=7, vertical 
bars represent the S.E.M. * denotes p<0.05, ** p<0.01 and *** p<0.001. Adapted 
from Paper IV. 
 
Bearing in mind that it in Paper I was demonstrated that the in situ half 
bladder model generates responses of the same, or if anything larger, 
magnitude after 30-60 minutes, and that any issues with the anesthesia 
wearing off would most likely cause an increase in reflexly-evoked 
contractions, the present results according to the effects of the antagonists are 
convincing. 
 
3.3.3 Conclusion of changes in 
cyclophosphamide- induced cystitis 
Besides the obvious macroscopic signs of inflammation, urinary bladders 
from CYP-treated rats showed a decrease in contractility. Even though a 
large part of the loss of function likely can be accredited to general muscle 
impairment, a change in the respective transmitter systems was also 
observed. In vitro, the rapid, phasic phase of the contraction was not found to 
be affected to any large extent by the inflammation, whereas the tonic phase 
was seen to become less sensitive to cholinergic antagonism during this 
condition (Paper III). In all, the purinergic part of the parasympathetic 
response was smaller, or at least not increased, in the CYP-treated rats, 
particularly at low stimulation frequencies. At certain stimulation 
frequencies, the cholinergic relative response remained unaffected in CYP-
treated rats, while at others it seemed to be reduced. This may reflect an 
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interaction between muscarinic and nitrergic systems (Andersson et al., 
2011). 
Generally, changes observed in the micturition reflex in patients with lower 
urinary tract disorders have been ascribed to the afferent part of the 
micturition, as reviewed by Daly et al. (2011). Furthermore, afferent nerves 
have been shown to be important in the development of CYP-induced cystitis 
(Ahluwalia et al., 1994; Maggi et al., 1992). In contrast to the in vitro 
findings in this thesis, the contractile response to methacholine, but not that 
to ATP, was reduced in rats with CYP-induced cystitis in the in situ setup 
(Paper IV). Interestingly, the contractions to ATP were atropine sensitive, 
which further stresses the intricate phenomenon of interaction between the 
purinergic and cholinergic systems. Furthermore, the stretch-induced 
response was elevated in cystitis and could to a large extent be blocked by 
purinergic antagonists, especially at stimulation of a lower magnitude. 
Previous observations have showed an increase in the release of ATP in 
animal models of BPS/IC (Birder et al., 2003) and in patients with painful 
bladder syndrome (Kumar et al., 2007). Increased levels of ATP have in turn 
been coupled to increased urinary frequency (Pandita et al., 2002), increased 
desire in OAB patients to void (Cheng et al., 2010) and sensitization of 
sensory P2X purinoceptors on afferent nerves in rats with CYP-induced 
cystitis (Dang et al., 2008). No findings in the current observations contradict 
this. On the contrary, the substantial difference between the stretch-induced 
responses in the normal and inflamed bladder is likely to be explained by this 
mechanism. Likely, other factors, such as NO, causing an increment of 
detrusor sensitivity or reactivity may also contribute to the large differences 
observed. 
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3.4 Impact of pre- treatments on 
cyclophosphamide- induced cystitis 
In the present thesis, urinary bladders from rats with CYP-induced cystitis 
and saline-treated control rats, pre-treated with either saline (as control) or 
one of the following substances; DPCPX (P1A1 purinoceptor antagonist, 
Paper V), PSB1115 (P1A2B purinoceptor antagonist, Paper V), suramin (P2 
purinoceptor antagonist, Paper V), 4-DAMP (muscarinic receptor antagonist, 
Paper VI) or L-NAME (NOS inhibitor, Paper VI) were compared. 
Bladders from CYP-treated rats were clearly affected, showing reddening and 
thickening of the bladder wall compared to control urinary bladders. There 
were, however, great variations in the macroscopic appearances, especially in 
inflamed bladders. Bladder preparations from CYP-treated rats were over all 
thicker, and also slightly heavier. There were, however, no statistically 
significant differences in bladder strip weight within the two groups (saline- 
and CYP-treated rats, respectively; Paper V). 
Functionally, contractions to both methacholine and ATP were investigated 
in Paper V and VI and although the response to methacholine proved to be 
somewhat more robust, also the ATP-evoked contractions provided valuable 
insights. Also, the relaxatory response to adenosine was studied (Paper VI). 
 
3.4.1 Functional studies 
The unspecific muscarinic agonist methacholine (50 nM - 5 mM) evoked 
significantly larger contractions in control rats pre-treated with saline than in 
CYP-treated, saline pre-treated rats in both studies (Paper V and VI). The 
contractions to methacholine invariably caused bell shaped concentration-
response curves which were modeled using a traditional Emax equation, 
excluding the highest concentration (Paper V) or a non-linear bi-phasic 
equation (Paper VI). This relation between the contractions to methacholine 
in saline- and CYP-treated rats was similar also in urinary bladder strip 
preparations from rats pre-treated with suramin or 4-DAMP (Paper V and 
VI). 
Pre-treatment with PSB1115 maintained, or if anything tended to further 
increase the observed difference between control rats and rats with cystitis 
(Paper V). Notably, the functional responses in specimens from rats pre-
treated with the P1A1 antagonist DPCPX were almost identical in controls 
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and rats with cystitis, suggesting a normalizing effect of this drug (Paper V; 
Fig. 17). Also preparations from rats pre-treated with L-NAME showed a 
normalized cholinergic response in CYP-treated rats compared to control 
(Paper VI). 
 
Figure 17. Mean contractile responses to methacholine in urinary bladder strip 
preparations from rats treated with saline () or CYP () and pre-treated with (A) 
saline; n=14-16 or (B) DPCPX; n=8-12. ** p<0.01 and *** p<0.001. Vertical bars 
represent the S.E.M. Adapted from Paper V. 
 
Similarly to what was observed in the response to methacholine, the 
unspecific P2 purinoceptor agonist ATP (5 – 500 µM) caused (Paper V) or 
tended to cause (Paper VI) larger contractions in saline pre-treated control 
rats than in saline pre-treated rats with CYP-induced cystitis. Pre-treatment 
with either suramin, PSB1115 (Paper V) or 4-DAMP (Paper VI) caused a 
decrement in contractile response to ATP in both saline-treated and CYP-
treated rats and no difference between the groups could be statistically 
proven. 
In the case of PSB1115 (Paper V) and L-NAME (Paper VI) a shift where 
inflamed bladder strips responded with greater magnitude than controls was 
seen, but the differences were minor and not statistically significant. DPCPX-
pretreatment, however, caused the ATP-evoked contractile response to be 
significantly higher in CYP-treated rats than in controls pre-treated with this 
antagonist, thus producing a response different than that evoked by 
methacholine. 
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The relaxations to adenosine (50 µM, Paper VI) were significantly larger in 
control specimens than in inflamed bladder strip preparations (-2.4±0.1 
(n=10) vs. -0.7±0.1 (n=12) mN; p<0.001). This was similar in the 4-DAMP 
pre-treatment group, whereas the difference in relaxation to adenosine was 
abolished in L-NAME pre-treated rats (Fig. 18). Even though the maximal 
relaxation in saline-treated, L-NAME pre-treated rats was smaller than in 
control specimens, the inflamed L-NAME pre-treated bladder strip 
preparations tended to respond to a larger extent than did the inflamed control 
strips. 
Figure 18. Mean relaxatory responses to adenosine (50 µM) of isolated urinary 
bladder strip preparations from control (saline-treated; white) rats and rats with 
CYP-induced cystitis (black), pre-treated with saline (n=10 and 12), 4-DAMP (n=8 
and 10) or L-NAME (n=8 in each group). The vertical bars represent the S.E.M. *** 
denotes p<0.001. From Paper VI. 
 
3.4.2 Bladder histology 
Microscopically, both the total bladder wall and the mucosa/submucosa were 
thicker in the preparations from CYP-treated rats (Paper V and VI). Also, the 
detrusor layer seemed more disorganized in CYP-treated bladders, and the 
mucosal and submucosal part of the bladder wall was found to be 
significantly smaller in normal bladder specimen (25.7 and 20.4% in saline 
pre-treated, saline-treated rats in Paper V and VI, respectively) compared to 
in rats with CYP-induced cystitis (46.3 and 42.6%, in Paper V and VI, 
respectively). Neither of the pre-treatments caused significant changes in 
mucosa and submucosa thickness in the saline-treated rats, even though 
DPCPX and possibly 4-DAMP and L-NAME tended to lower this parameter. 
In the CYP-treated animals on the other hand, pre-treatment with DPCPX 
Purinergic Effects in the Rat Urinary Bladder 
64 
(Paper V, Fig. 19) and L-NAME (Paper VI) caused a significant reduction in 
mucosa and submucosa thickness, compared to preparations from rats with 
CYP-induced cystitis pre-treated with saline. 
Figure 19. Mean mucosa and submucosa thickness, expressed as percent of total 
bladder wall, in urinary bladders from rats pre-treated with saline (Sal), DPCPX, 
PSB1115 or suramin and treated with either saline (Sal) or cyclophosphamide 
(CYP). n=5 in each group, * denotes p<0.05 (between Sal-CYP and DPCPX-CYP) 
and ** denotes p<0.01 (between saline-treated and CYP-treated bladders). Vertical 
bars represent the S.E.M. From Paper V. 
 
3.4.3 Mast cells 
No significant difference was observed in the total number of mast cells 
(colored by toluidine blue), but the percentage of mast cells found in the 
detrusor vs. the total mast cell count was over all greater in CYP-treated rats, 
compared to control (Paper V and VI). Interestingly, L-NAME pre-treatment 
(Paper VI) abolished any statistically significant difference between the two 
groups (Fig. 20), whereas DPCPX, and possibly also PSB1115, tended to 
cause a reduction of this ratio in bladders with CYP-induced cystitis. 
Specimens treated with saline did not appear to undergo any notable changes. 
This is in line with previous studies where an increase of mast cells in the 
detrusor in patients have been suggested to be an early marker of BPS/IC 
(Frazer et al., 1990), and has even been shown to be a possible factor 
discriminating between different forms of BPS/IC (Peeker et al., 2000). Even 
though some studies claim toluidine blue staining and fixation in 
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formaldehyde to cause underestimation of the degree of mastocytosis 
(Aldenborg et al., 1986; Theoharides et al., 2001), this should not be a major 
concern in the current studies, since all preparations were treated in the same 
fashion.  
Figure 20. Ratio of toluidine blue stained mast cell occurrence in the detrusor 
compared to in the whole bladder wall in urinary bladders from rats pre-treated with 
saline,4-DAMP or L-NAME, treated with either saline (white) or CYP (black). n=3 
in each group, ** denotes p<0.01 and *** denotes p<0.001. Vertical bars represent 
the S.E.M. From Paper VI. 
 
3.4.4 Immunohistochemistry  
MIF- and muscarinic M5 receptor-like immunoreactivity were detected in 
CYP-treated, as well as control, bladder preparations (Fig. 21 and 22). The 
MIF-like staining showed a large variation in the treatment groups, and no 
certain conclusions could be drawn. There seemed, however, to be a 
difference in the distribution of the MIF-like expression; in urinary bladders 
from saline treated rats it was localized to the basal part of the urothelium, 
whereas in CYP-treated specimens the staining seemed to be more widely 
spread across the urothelium (Paper V and VI), which corresponds to other 
reports where changed levels of urothelial MIF and increased MIF-levels in 
the urine have been observed during inflammation (Meyer-Siegler et al., 
2004b; Vera et al., 2008). Pre-treatment with DPCPX, but not L-NAME, 4-
DAMP, PSB1115 or suramin, seemed to reduce the more diffuse 
immunoreactivity in CYP-treated rats although, as previously mentioned, 
these results should be interpreted with caution. The P1A1 purinoceptor-like 
immunoreactivity (Paper VI) seemed slightly lowered in inflamed bladder 
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specimens, and may have been slightly elevated after L-NAME pre-
treatment, but these results should be interpreted with care. 
Regarding the muscarinic M5 receptor-like expression, it was shown to be 
elevated during CYP-induced cystitis (Paper V and VI), as has been reported 
previously (Giglio et al., 2005). This increase in immunoreactivity in CYP-
treated rats, compared to control rats treated with saline, was inhibited by 
pre-treatment with DPCPX (Paper V) or L-NAME (Paper VI). Also pre-
treatment with suramin seemed to lower the muscarinic M5 receptor-like 
expression in CYP-treated rats, however to a much lower degree than did 
DPCPX. PSB1115 pre-treatment appeared to possibly decrease this staining 
in preparations from rats treated with either CYP or saline, although to a 
lower extent, whereas 4-DAMP caused no changes in muscarinic M5 
receptor-like immunoreactivity. 
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Figure 21. Sections of urinary bladder stained with antibodies targeting the 
muscarinic M5 receptor from rats pre-treated with DPCPX (A, B) or saline (C, D) 
and treated with saline (upper row A, C, E) or CYP (bottom row B, D, F). Also 
shown are negative controls of sections C and D (E and F, respectively). Green color 
represents muscarinic M5 receptor-like expression, red and blue color represents 
phalloidin and DAPI, respectively. Adapted from Paper V. 
 
 
Figure 22. Sections of urinary bladder stained with antibodies targeting macrophage 
migration inhibitory factor (MIF) from rats pre-treated with saline (A, B) or DPCPX 
(C) and treated with saline (A) or CYP (B, C). Green color represents MIF-like 
distribution, red and blue color represents phalloidin and DAPI, respectively. 
Arrows indicate the basal part of the urothelium. Adapted from Paper V. 
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3.4.5 Conclusion of impact of pre- treatments on 
cyclophosphamide- induced cystitis 
Even though the main scope of the studies (Paper V and VI) was to 
characterize the functional contractile changes in the treatment and pre-
treatment groups, other parameters regarded to be of interest in the evaluation 
of the development of cystitis were also looked upon. The studies were 
designed and performed to first and foremost investigate changes between 
controls and CYP-treated rats within each pre-treatment group, rather than to 
the saline pre-treatment. Thus, comparisons of individual concentration-
response curves between the pre-treatment groups must be made with 
caution, even though being discussed to some extent in this thesis. 
Taken together, the normalized contractile response to methacholine seen 
after pre-treatment with DPCPX and L-NAME (Paper V and VI) might have 
to some extent been due to a decreased contractile function in saline-treated 
rats. However, a decreased inflammatory damage to the urinary bladder in 
these animals undoubtedly played a significant role since a number of 
parameters regarded to occur in CYP-induced cystitis were affected. 
Normalizing changes in relaxatory response, histological examinations, 
muscarinic M5 receptor expression, mast cell count etc. support the statement 
that the inflammation was alleviated, suggesting both NO and the P1A1 
adenosine receptor to be of importance in the regulation of bladder 
inflammation. A prominent alteration in CYP-induced cystitis is the bladder 
wall thickening, to a large part caused by edema (Cox, 1979; Crocitto et al., 
1996; Terado et al., 2005). This may be an important factor hampering the 
contractile capacity, possibly by just mechanically counteracting the strength 
of the muscle contraction. This may also, just by passive stretch, cause the 
bladder to persist in a state at which it is more close to the threshold for a 
stimulus to evoke a reflex response. DPCPX and L-NAME reduced the 
mucosa thickness, which might make them suitable in the treatment of 
bladder inflammation.  
Since a link has been seen between adenosine acting on P1A1 purinoceptors 
and the production and release of NO in endothelial cells (Ray et al., 2002), 
and since NO has previously been investigated in the context of 
inflammation, the effect of L-NAME on CYP-induced cystitis was also 
studied. Even though intravesical administration of a NO-donor has been 
shown to suppress CYP-induced bladder hyperactivity (Ozawa et al., 1999), 
blockade of iNOS with the inhibitor aminoguanidine has been described to 
prevent some of the fibrotic changes occurring in rodents during bladder 
outlet obstruction (Felsen et al., 2003). The administration of L-NAME and 
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other NOS inhibitors to rats with CYP-induced cystitis also has been studied 
previously (Oter et al., 2004; Souza-Fiho et al., 1997). In these studies, 
however, other non-functional parameters, such as extravasation, were 
studied and the experiments were conducted over a shorter period of time. 
The conclusion in this thesis regarding a protective role of NOS blockade 
thus seems feasible. 
In a very recent study, administration of the P1A1 purinoceptor agonist 
CCPA, which effects can be inhibited by DPCPX, was shown to worsen the 
bladder hyperactivity symptoms in rats with CYP-induced cystitis (Prakasam 
et al., 2012). This is in concordance with our current findings that the P1A1 
purinoceptor is a proinflammatory receptor which also seems to mediate 
functional effects in both healthy and inflamed urinary bladders. However, 
since the expression of the P1A1 purinoceptor shows great plasticity over 
time in inflammation (Save et al., 2009), the duration of the inflammation 
ought to be addressed in future studies. 
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4 GENERAL DISCUSSION 
The concept of ATP being an important chemical transmitter is now widely 
accepted (Burnstock, 2013). This was, however, not the case for many years 
after this had first been suggested. Initial criticism was directed towards the 
notion that it “seemed odd” that the body would “waste” precious energy in 
this manner to transmit signals and that it was a much too common molecule 
in the body to produce specific responses (every day the human body is 
estimated to turn over an amount of ATP equal of its body weight (Tornroth-
Horsefield et al., 2008)). However, the discovery and characterization of 
specific receptors and interactions with other transmitter systems etc. have 
provided solid evidence of ATP being, if not a classical, a true transmitter 
indeed. In vitro, relatively high concentrations of ATP are often needed to 
elicit a functional response. The P2X1 purinoceptor, which is responsible for 
the major part of the purinergic direct contractile response of the urinary 
bladder, has been shown to be readily desensitized by low concentrations (in 
the range of nM) of ATP, which may mask the true potency of this agonist 
(Rettinger et al., 2004). 
The fact that ATP is a common molecule, capable of acting on many receptor 
subtypes, that also yields active metabolites further contributes to the 
complexity of the purinergic signaling. Furthermore, many steps in the 
release and breakdown of ATP, as well as in the expression of purinoceptors 
and interactions with other transmitter systems can be altered under 
pathological conditions, such as during the course of inflammation. This 
thesis pinpoints the significance of interactions between signaling systems in 
the regulation of urodynamic functions in the urinary bladder. It shows that 
these interactions may occur on a neuronal or non-neuronal level, and may 
affect both efferent and afferent signaling. Furthermore, disease, e.g. 
inflammation of the urinary bladder, may substantially alter any single 
component with great impact on the composite functional response.  
The complexity of the bladder responses may be one reason for the unclear 
situation in patients, leading to a pharmacotherapy with often suboptimal 
outcome and less than well understood mechanisms of action. It may also 
explain some of the difficulties in establishing the role of NANC transmitters 
in the human situation. For instance, anticholinergic drugs have for a long 
time been used in the treatment of incontinence and overactive bladder. Very 
recently, mirabegron, a new beta-3 adrenoceptor agonist (Igawa et al., 2012) 
has been developed as a bladder relaxant used in the treatment of overactive 
bladder. Currently, no drug acting on purinoceptors is available for the 
treatment of diseases in the lower urinary tract, even though work is carried 
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out to identify substances acting on purinoceptors on sensory neurons in the 
bladder (Gever et al., 2010). The results in this thesis, suggesting an 
increased role of afferent, but not necessarily efferent, purinergic signaling in 
CYP-induced cystitis, supports the idea that a purinergic tool aimed at 
afferent purinoceptors would seem to be the preferable option when treating 
symptoms in the lower urinary tract. 
If the role of the purinoceptors in direct bladder function is, or has been, 
considered to be a bit unorthodox, the fact that ATP and adenosine, by acting 
on their respective purinoceptors, are able to affect the course of 
inflammation is less controversial. Different purinoceptor subtypes are 
known to act in both pro- and anti-inflammatory manners, depending on the 
situation (e.g. level of inflammation) and tissue (Kruse et al., 2012; Wilson et 
al., 2009). Their involvement in these processes is complex. However, by 
interacting with other systems, the purinoceptors are likely to have a large 
impact on the development of inflammatory conditions. 
In this thesis, the relevance of the adenosine P1A1 purinoceptor in the 
development of CYP-induced urinary bladder inflammation is highlighted. 
Beneficial effects to blockade of this purinoceptor subtype, as well as of the 
synthesis of NO, were in the current studies seen during cystitis. Antagonism 
of muscarinic receptors was also investigated due to possible interactions 
with the purinergic system and well-established clinical use, but no impact on 
the course of inflammation was seen. Certainly, more studies need to be 
conducted in order to confirm these findings; other lower urinary tract disease 
models should be used to study the generalizability of this mechanism, other 
doses and antagonists with similar, but not identical, pharmacological 
profiles ought to be tested and other routes of administration should be tried 
to optimize clinical effect and minimize the risk of unwanted side effects 
occurring. Moreover, the impact of P1A1 purinoceptor- or NOS blockade 
after the induction of cystitis, i.e. when the inflammation already is a fact, 
ought to be addressed to further increase clinical relevance. Nonetheless, the 
current findings regarding pre-treatment present valuable insights about the 
role of purinoceptors and NO in the development of cystitis. 
The principal role of purines must be discussed. The results in this thesis, 
together with many other studies, suggest a direct functional significance of 
ATP and adenosine in the rat, both in the normal state and during urinary 
bladder inflammation. Currently, both contractile and relaxatory functional 
purinoceptors have been characterized and the impact of purinergic signaling 
in the normal state and during cystitis scrutinized. Undoubtedly, 
purinoceptors play an important role in many species, including territory 
Purinergic Effects in the Rat Urinary Bladder 
72 
marking animals, and most likely also in man during pathological conditions. 
Regarding efferent functional contractility, ATP should be regarded not as 
the main player, but as a modulating transmitter besides acetylcholine and, to 
some extent, noradrenaline. In the pathological state, alterations regarding 
purinergic function are seen predominantly on the afferent side. The ability of 
the purinoceptors to affect both the course of inflammation, altered afferent 
signaling and bladder smooth muscle contraction make them a very 
interesting target for pharmacological treatment of symptoms in the lower 
urinary tract, for instance in BPS/IC. 
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5 CONCLUDING REMARKS 
In this thesis, several methods have been employed to study the purinergic 
impact on rat urinary bladder function in the normal state and during CYP-
induced cystitis, and a novel in situ experimental setup has been described. 
Also, the impact of purinergic, cholinergic and nitrergic pre-treatment on the 
development of inflammation has been addressed. 
Functionally, the contractile purinergic function was, as is in concordance 
with previous findings, found to be mediated by the P2X1 purinoceptor. 
Relaxatory purinergic responses were in the normal rat found to be elicited 
by P2Y purinoceptors with different sensitivities for ADP/ATP and 
UDP/UTP, as well as by the P1A2B purinoceptor. A purinergic phase of EFS-
evoked contractions was clearly identifiable, which did not seem to increase 
in importance during cystitis. 
A novel in situ experimental setup, enabling the study of contralateral 
contractile responses to stretch-evoked afferent stimuli, was designed and 
employed. In contrast to in vitro, purinergic contractions were not reduced 
during cystitis in situ and the stretch-induced contractions were markedly 
increased. This reflex was found to exert a composite response mediated by 
both muscarinic receptors and P2 purinoceptors, where the latter are of 
greater importance at lower stimulation intensities. Generally, when efferent 
responses (agonist- or nerve-evoked) are studied, they are reduced, or at least 
not increased, in CYP-treated rats. The enhancement in the reflexly evoked 
contractions in situ is thus likely to occur in either the afferent part of the 
reflex, or in the transmission in the central nervous system. The novel in situ 
model offers many interesting possibilities for future studies. 
Pre-treatment with either P1A1 purinoceptor antagonist or NOS inhibitor was 
shown to alleviate the change in contractile function to CYP-induced bladder 
inflammation, which was confirmed by the study of several inflammatory 
findings common in cystitis. 
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Figure 23. Tentative overview of purinergic, cholinergic and nitrergic interplay in 
the afferent and efferent control of the detrusor discussed in this thesis. CYP-
treatment causes cystitis with many observable effects in the urinary bladder. Many 
of these changes can be alleviated with P1A1 or NOS-blockade. Arrows within red 
boxes indicate changes during CYP-induced cystitis. The afferent purinergic 
signaling, such as during stretch, seems to be of greater importance during cystitis. 
Muscarinic M3 receptors and P2X1 purinoceptors are considered to be functionally 
contractile, whereas muscarinic M5 receptors and urothelial P2 purinoceptors are 
mediating relaxation, probably by an NO-coupled mechanism. Adenosine P1A2B (and 
P1A1) purinoceptors also mediate relaxation, as does receptors of the P2Y family. 
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